{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Text Suammarization"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from nltk.tokenize import sent_tokenize\n",
    "from lexrank import STOPWORDS, LexRank"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Year</th>\n",
       "      <th>Topic</th>\n",
       "      <th>Content</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>When and where did the 2006-07 flu season start?</td>\n",
       "      <td>The first report of regional flu activity came...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>How severe was the 2006-2007 flu season?</td>\n",
       "      <td>The 2006-07 flu season was generally mild comp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>What determines the severity of a flu season?</td>\n",
       "      <td>The overall health impact (e.g., infections, h...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>Where did the most flu activity occur in the U...</td>\n",
       "      <td>Influenza viruses were identified in all state...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>When did the 2006-2007 flu season peak?</td>\n",
       "      <td>During the 2006-2007 season, flu activity in t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>136</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>Updates to the Advisory Committee on Immunizat...</td>\n",
       "      <td>A couple of things are different for the 2023-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>Updates to U.S. Flu Surveillance Methods for t...</td>\n",
       "      <td>Starting with the 2023-2024 influenza season, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>138</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>B/Yamagata and Flu Vaccines Summary</td>\n",
       "      <td>Quadrivalent flu vaccines protect against four...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>Coinfection: Getting More than One Respiratory...</td>\n",
       "      <td>It is possible to get sick with more than one ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>Flu, RSV, and COVID-19 Coinfection Data: 2023-...</td>\n",
       "      <td>One way CDC collects data on coinfections with...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>141 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          Year                                              Topic  \\\n",
       "0    2006-2007   When and where did the 2006-07 flu season start?   \n",
       "1    2006-2007           How severe was the 2006-2007 flu season?   \n",
       "2    2006-2007      What determines the severity of a flu season?   \n",
       "3    2006-2007  Where did the most flu activity occur in the U...   \n",
       "4    2006-2007            When did the 2006-2007 flu season peak?   \n",
       "..         ...                                                ...   \n",
       "136  2023-2024  Updates to the Advisory Committee on Immunizat...   \n",
       "137  2023-2024  Updates to U.S. Flu Surveillance Methods for t...   \n",
       "138  2023-2024                B/Yamagata and Flu Vaccines Summary   \n",
       "139  2023-2024  Coinfection: Getting More than One Respiratory...   \n",
       "140  2023-2024  Flu, RSV, and COVID-19 Coinfection Data: 2023-...   \n",
       "\n",
       "                                               Content  \n",
       "0    The first report of regional flu activity came...  \n",
       "1    The 2006-07 flu season was generally mild comp...  \n",
       "2    The overall health impact (e.g., infections, h...  \n",
       "3    Influenza viruses were identified in all state...  \n",
       "4    During the 2006-2007 season, flu activity in t...  \n",
       "..                                                 ...  \n",
       "136  A couple of things are different for the 2023-...  \n",
       "137  Starting with the 2023-2024 influenza season, ...  \n",
       "138  Quadrivalent flu vaccines protect against four...  \n",
       "139  It is possible to get sick with more than one ...  \n",
       "140  One way CDC collects data on coinfections with...  \n",
       "\n",
       "[141 rows x 3 columns]"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "content = pd.read_csv('data/flu_data_topic_cleaned.csv')\n",
    "content"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Lex Rank"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "141"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents = content['Content'].values\n",
    "\n",
    "len(documents)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "all_tokenized_sentences = [sent_tokenize(str(document)) for document in documents]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "141"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(all_tokenized_sentences)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[1. 1.]\n",
      "[1.02248742 1.10929753 1.00336564 1.05049071 0.78764082 1.02671788]\n",
      "[1. 1.]\n",
      "[1. 1.]\n",
      "[1.08774137 1.10064971 0.81160892]\n",
      "[0.91212052 0.93318623 1.02106161 0.99427119 1.12449406 1.1252169\n",
      " 1.16039342 0.72925608]\n",
      "[1.09011562 1.11969352 0.86646817 0.92372269]\n",
      "[1.03644534 0.84351606 0.96020766 1.11921817 1.07632299 0.99786103\n",
      " 0.96642874]\n",
      "[0.9756008  0.97200254 1.05239666]\n",
      "[0.95015923 0.69496309 0.99397656 0.92689799 0.85390525 1.04811204\n",
      " 1.10591665 1.01025247 1.19507125 1.10503415 1.11571131]\n",
      "[1. 1.]\n",
      "[1. 1.]\n",
      "[1. 1.]\n",
      "[1. 1.]\n",
      "[0.98011586 0.9872536  1.03263054]\n",
      "[1. 1.]\n",
      "[0.9843219  1.16762751 1.07018641 1.01740531 0.76045888]\n",
      "[0.57075795 1.09616619 0.93942042 1.00573697 0.68416    1.21503122\n",
      " 1.19577343 1.36574514 1.04644866 0.66414467 1.36911091 1.29483442\n",
      " 0.61871564 0.69063099 1.2433234 ]\n",
      "[0.96782825 1.11825252 1.16138387 1.0237552  0.72878017]\n",
      "[0.74991273 1.1867324  0.94976209 1.11359278]\n",
      "[0.988503   0.95824556 1.23689327 1.01300907 0.70216101 1.10118809]\n",
      "[1.08754767 1.03819044 1.15034651 0.95297006 0.99901366 0.77193166]\n",
      "[1. 1.]\n",
      "[1.08666521 1.23743426 0.77102158 1.07743319 0.83454427 0.99290149]\n",
      "[1.]\n",
      "[0.89030704 0.89256979 1.11826401 1.09885916]\n",
      "[0.85179907 0.87612265 1.14231819 0.92712872 0.92968751 1.27294386]\n",
      "[0.73655798 1.19721538 0.99197862 1.06314875 1.10978625 1.15124347\n",
      " 0.75006956]\n",
      "[1. 1.]\n",
      "[0.87583765 0.99292456 0.98503621 0.77063036 0.93469816 1.11562061\n",
      " 1.22999914 1.09525331]\n",
      "[1. 1.]\n",
      "[1. 1.]\n",
      "[1.09794114 1.07453647 1.02144737 0.80607502]\n",
      "[1.01482933 1.07336373 1.00618935 0.84364938 1.04634676 1.01562146]\n",
      "[0.96344856 1.02049249 1.01605895]\n",
      "[1.10606085 1.13388547 0.86987079 0.8056504  1.0845325 ]\n",
      "[0.85449376 1.13413256 0.96681424 1.16761486 0.87694458]\n",
      "[1.1146088  0.81783131 1.05377956 0.9831806  1.29276495 0.89593901\n",
      " 0.84189577]\n",
      "[1. 1.]\n",
      "[0.89432109 0.84768752 1.0561222  1.10459742 0.9734856  1.13868598\n",
      " 0.98510019]\n",
      "[1.08541003 1.04835616 0.90275164 1.11464479 0.84883738]\n",
      "[1. 1.]\n",
      "[1.00122995 1.02834525 0.97042479]\n",
      "[1.12233312 0.7828682  1.09893239 0.99586629]\n",
      "[1.15893015 1.06124247 0.86591164 1.13168383 0.62761836 1.15461354]\n",
      "[0.84035971 1.04091273 0.99328958 1.08668134 1.07868718 0.90277209\n",
      " 1.05729738]\n",
      "[0.97800576 1.17998342 0.87510832 0.9944518  1.09101198 0.88143872]\n",
      "[0.56508792 1.11710567 0.97034327 0.93567054 1.19644101 1.03283287\n",
      " 1.18251872]\n",
      "[1.         1.03138869 0.95166426 1.00763561 1.06743746 0.79312409\n",
      " 1.12483287 1.16100534 1.21816141 0.64475027]\n",
      "[0.97504745 0.9638475  1.06110505]\n",
      "[1.03679308 0.96063974 1.00256718]\n",
      "[1.05191673 1.04066241 0.90742086]\n",
      "[1. 1.]\n",
      "[1.]\n",
      "[1.]\n",
      "[1.14187666 1.1852279  0.85316384 1.09160262 0.72812899]\n",
      "[0.80758773 1.04657945 1.05642855 1.08940427]\n",
      "[1.00984145 0.71263502 1.05770848 1.08868771 1.13112733]\n",
      "[1.033554   1.02116225 0.94528375]\n",
      "[1.05734665 1.03454717 0.95510955 0.73309371 1.06825299 1.11429654\n",
      " 1.03735339]\n",
      "[0.96803952 0.98323049 1.04872998]\n",
      "[1.02891029 0.96004372 1.16888922 1.00179945 0.93522648 0.96737587\n",
      " 0.93775497]\n",
      "[0.96344856 1.02049249 1.01605895]\n",
      "[1. 1.]\n",
      "[0.92183836 1.06833477 1.00982687]\n",
      "[1.03822588 1.04339337 0.90263678 0.86615212 0.8831308  1.19541521\n",
      " 0.97182945 1.09921638]\n",
      "[1.07478476 0.95058761 1.18094254 0.93673677 0.85694832]\n",
      "[1. 1. 1.]\n",
      "[0.90472464 0.88571653 1.09797762 1.20219313 1.21056551 0.65146877\n",
      " 1.06614654 0.98120725]\n",
      "[0.95054262 1.03809084 1.07133881 0.94002773]\n",
      "[1.21295422 0.72715853 0.68424046 1.20685681 1.14466672 1.14046429\n",
      " 0.88365897]\n",
      "[1. 1.]\n",
      "[1.02768789 1.0422582  1.16202184 0.99231612 0.77571595]\n",
      "[0.94804663 1.0398487  1.01210467]\n",
      "[1. 1.]\n",
      "[0.89808807 1.00797376 1.11947285 0.74142678 1.06114006 1.19506165\n",
      " 1.28552638 0.69131045]\n",
      "[1.06004216 1.10231554 0.83764231]\n",
      "[1. 1.]\n",
      "[1.03641529 0.96146867 1.00211604]\n",
      "[1.]\n",
      "[1.07562548 1.1759907  1.05923972 0.6831894  1.16022162 1.09701214\n",
      " 0.96589791 0.84811226 0.88009398 1.05461679]\n",
      "[1. 1.]\n",
      "[0.96862178 1.18223236 1.04554137 0.93641496 0.99748365 1.0403059\n",
      " 0.82939998]\n",
      "[0.82847753 1.08031996 0.93594594 1.10546187 1.0497947 ]\n",
      "[1.01390478 0.8407077  0.94339671 1.16435941 1.0376314 ]\n",
      "[0.93654655 0.96316421 1.10028924]\n",
      "[1.01973668 0.88822638 1.09203694]\n",
      "[1.07987819 0.88003856 1.15859363 1.06756808 0.81392154]\n",
      "[0.8962332  1.05834023 1.04418252 1.00124404]\n",
      "[0.95650823 1.11960237 0.9238894 ]\n",
      "[0.80726924 1.14927082 0.99470046 1.19678945 0.74783668 1.10413335]\n",
      "[1.18220249 0.83817079 1.12047196 1.03827892 1.03990456 0.78097129]\n",
      "[0.49018285 0.56566386 1.02295924 1.08866478 0.97876257 0.69648628\n",
      " 1.30803555 1.36464094 1.25879857 1.30787303 1.06184132 1.25879857\n",
      " 0.59729243]\n",
      "[1.13078814 0.85443673 0.90411437 1.16582291 0.94483785]\n",
      "[0.94109381 1.07452909 0.9843771 ]\n",
      "[0.94243386 1.04657199 1.01099415]\n",
      "[0.99995166 0.96671524 1.07065864 0.96267446]\n",
      "[1.11732336 1.11435376 1.17273573 0.92251505 1.01195859 0.80017529\n",
      " 0.86093822 1.        ]\n",
      "[1. 1.]\n",
      "[1.00883281 0.95667012 1.03449708]\n",
      "[1.         1.03811783 1.12380285 1.14316343 1.00130457 0.96657284\n",
      " 0.72703847]\n",
      "[1.]\n",
      "[1.13357696 1.03735867 0.89660385 0.93246051]\n",
      "[1.33112553 0.71579734 0.84925255 1.18854834 0.97944296 1.20592649\n",
      " 1.51691849 0.72646805 1.1641736  1.28880358 0.9411929  0.52915313\n",
      " 0.59504254 0.75686862 0.35810734 1.43489269 0.81033997 1.16520773\n",
      " 1.37666273 0.68014632 0.6045158  0.93688532 0.91167878 1.12011896\n",
      " 0.86552493 1.27248606 1.08215896 0.89036168 1.46794614 1.23425247]\n",
      "[0.70114114 1.24957984 1.26531793 0.6411723  0.77078933 0.62227654\n",
      " 0.61937499 1.46864624 1.28152378 1.0486314  1.14198114 1.08883849\n",
      " 0.80011267 0.57214204 1.07194112 1.24897848 0.89088896 1.29963659\n",
      " 0.87263617 1.07907289 1.26531793]\n",
      "[0.91787715 1.09289366 0.82700465 1.16874305 0.58638149 1.10853591\n",
      " 0.97233432 1.1819264  1.14430337]\n",
      "[1.27265375 1.25439017 0.64323101 1.26154312 1.23240585 0.7853174\n",
      " 0.89068509 0.96446231 1.21873264 0.9402585  1.04783304 0.92454096\n",
      " 0.78861095 0.77533521]\n",
      "[1.32080413 0.94589345 1.13355858 1.         1.10247961 0.72392415\n",
      " 0.94821332 1.28342737 1.0176346  1.19177437 0.74459395 1.02025526\n",
      " 0.81361341 0.63106219 0.87094113 1.29043489 0.96138958]\n",
      "[1.1486493  0.77337664 1.1539109  0.72631372 0.95363867 1.17330959\n",
      " 1.07790509 0.889787   1.05797387 0.96272275 1.08241247]\n",
      "[0.97753558 0.96569919 1.05676522]\n",
      "[1.04999468 1.02822377 1.16271707 0.75906448]\n",
      "[0.80128689 1.01824573 1.01067436 0.77184635 1.30662998 1.04149734\n",
      " 0.82274873 1.12525549 1.1803107  0.78453883 1.06333704 1.07362857]\n",
      "[1.11568209 1.14974067 0.89220954 0.60833988 1.23402782]\n",
      "[1.0129582  0.96969992 1.05354246 0.87632217 1.08747725]\n",
      "[1. 1.]\n",
      "[1.01650232 0.93290287 1.10566658 0.94492823]\n",
      "[1.4400025  1.15942442 0.75313573 0.58579839 1.23225872 1.11242494\n",
      " 0.66584581 1.05440197 0.99670752]\n",
      "[1. 1.]\n",
      "[0.84993693 1.08717528 1.00980894 1.05307886]\n",
      "[1.27799018 1.32632787 0.87207612 1.52762174 1.00339284 1.18078673\n",
      " 1.32486133 1.34349579 0.82002408 0.92690465 1.0528096  0.86520016\n",
      " 1.41840846 1.57873047 0.80560918 0.90862758 1.33510396 1.0688857\n",
      " 0.88266623 1.13506145 1.68079498 0.76310914 1.14961129 1.3701838\n",
      " 1.12567589 0.43856053 0.86958643 0.29567097 1.68207811 0.96191531\n",
      " 1.13125973 1.02082184 1.35047567 0.68990962 0.62308133 0.92759345\n",
      " 1.54192267 1.15215169 0.72290028 1.63256821 0.48940103 1.11287205\n",
      " 1.06910024 0.92470656 1.30341994 1.38361212 1.47986766 0.9736308\n",
      " 0.76080964 1.61261713 0.48940103 1.11287205 0.86657335 0.99255712\n",
      " 0.9580861  0.80376834 1.44196594 1.1932631  1.07049252 0.58373588\n",
      " 0.8452783  0.48940103 1.08600516 1.20369126 1.43200994 0.80680871\n",
      " 0.85944464 1.07517314 0.76080964 0.97714812 1.69423542 1.31847518\n",
      " 1.09014781 0.81537309 0.40099508 0.95232452 1.39604697 0.41884916\n",
      " 1.37004399 1.06803227 0.07735234 1.17568272 1.22142991 0.3866412\n",
      " 0.80139881 1.16924147 0.87259299 1.06407088 0.79596815 0.66292965\n",
      " 1.37178948 1.07878039 1.09014781 0.64713118 1.14320134 0.67440796\n",
      " 0.78409242 1.22648406 1.39407002 0.71336266 0.90292414 0.94625438\n",
      " 0.90407955 1.00903353 1.34349579 0.26694669 0.79176009 1.46703605\n",
      " 0.56558113 0.67174529 0.70531223 1.08225884 0.99531689 0.81920317\n",
      " 0.32886343 0.97009327 0.81738273 1.28771128 0.65640871 1.23470206\n",
      " 0.65815702 1.34784521 1.09077128 1.36929522 0.82378025 1.08493744\n",
      " 1.69115986 0.07735234 0.88889665 1.22073396 1.35585417 0.91205611\n",
      " 1.25055388 0.93681866 0.49150101 1.50759042 0.12397842 0.57360137\n",
      " 1.17773371 1.6144533  1.42323278 0.65241209 1.1730053  1.29206263\n",
      " 1.6561139  1.74522701 1.5624654  0.72395055 1.04570222 1.43597501\n",
      " 1.58015844 1.00497632 0.96216441 1.18942173 1.00960683 0.60135612\n",
      " 0.68339264 0.75857281 0.86639127 0.55756786 0.67595159 1.11707553\n",
      " 1.01471013 0.75535412 0.86393185 0.91052744 1.16106508 0.74916731\n",
      " 0.52271119 0.91800954 1.14360697 1.08007214 0.38839658 0.79400203\n",
      " 0.71823135 0.60622386 0.87187135 0.50697664 1.01322608 1.19599524\n",
      " 0.44628082 1.12825584 1.16384804 1.46664174 0.98031786 0.39158377\n",
      " 1.43618306 0.86135224 1.24473085 1.09964216 1.37190083 0.84403923\n",
      " 0.75196742 0.63727097 1.14327461 1.29252001 1.02787314]\n",
      "[1.30102089 1.25235391 1.22047735 0.95975353 0.54174989 1.2342125\n",
      " 1.10165541 0.70112765 1.01293644 1.05829696 0.38433538 1.27761557\n",
      " 0.83024225 1.12422228]\n",
      "[1.10374336 1.05735877 1.23700022 1.19135222 0.91559923 1.27460188\n",
      " 1.23031336 1.29162883 0.88841025 0.58319762 1.18353268 0.8362254\n",
      " 1.07335896 1.08273632 0.51578928 0.80989404 1.05151081 1.47416995\n",
      " 1.14533658 1.29302242 1.09574217 0.9846257  0.66994123 0.74978888\n",
      " 0.55325235 0.95022278 0.75764473]\n",
      "[1.01381924 1.02009325 0.96608752]\n",
      "[0.81150754 1.12326412 0.65440742 0.87210738 1.19632142 0.88225126\n",
      " 1.17540521 1.00788769 1.37613517 0.90071279]\n",
      "[1.19571399 0.38223628 1.20899512 0.95353876 1.03304836 0.79542158\n",
      " 0.9687306  1.05740329 1.51849352 1.02761728 1.07530598 1.25329794\n",
      " 1.15901084 0.31912268 0.96093697 0.18346369 0.74759258 1.4944117\n",
      " 0.97114967 1.00288433 1.12542952 1.15030358 1.19562833 1.19092363\n",
      " 0.83761621 1.08919307 0.48750114 1.07628119 1.44906986 0.46180714\n",
      " 1.41728679 1.12969653 1.0112104  1.16622289 1.09878075 0.90026178\n",
      " 1.03267356 0.76185226 1.22996022 1.11080569 1.11625085 0.70771638\n",
      " 0.55689815 1.21543502 0.98189629 1.19092363]\n",
      "[1.06359143 0.82435268 1.11396594 1.02978254 0.94758566 1.19790555\n",
      " 1.21035299 0.69705518 0.90720448 0.90259237 0.96552935 1.16892563\n",
      " 0.63380466 0.94553382 1.18501989 1.23420102 0.97259681]\n",
      "[0.68355316 0.97343344 0.80690115 1.24414404 1.3876515  1.18975483\n",
      " 1.03581186 0.40465072 1.01396307 1.10257841 1.2614753  1.08113558\n",
      " 0.67465174 0.8001617  0.97088492 1.31728138 1.38543834 1.26907073\n",
      " 0.43117401 1.18000666 0.89057298 1.18905675 1.32415919 0.75143502\n",
      " 0.63105349]\n",
      "[0.98008838 1.03636586 0.72608644 0.77890682 0.80145575 1.13269485\n",
      " 1.0172247  0.67150517 0.8837107  1.20540956 1.0665392  0.82142153\n",
      " 0.95168904 1.28329286 1.12412367 1.29029994 0.84636236 0.80307661\n",
      " 1.22656274 1.21094354 1.38491575 0.73482596 1.32180203 1.25521799\n",
      " 0.77710596 0.61735947 0.90232    0.8020532  1.27617638 1.13197318\n",
      " 0.89860238 0.91670337 1.10503617 0.96317113 1.40655646 1.07361093\n",
      " 0.57480989]\n",
      "[0.71212413 1.26845486 0.95092259 1.03753185 1.18541544 1.05516324\n",
      " 1.180332   0.85590739 1.21421117 0.54763247 1.22027054 0.53335075\n",
      " 0.97741911 1.26363571 0.99762875]\n",
      "[1.36283918 1.08050185 1.24265251 1.20078216 1.27431232 1.30551522\n",
      " 1.12696573 0.93695234 1.12283839 1.31270938 1.21150095 1.60020616\n",
      " 1.12872324 1.22754518 1.09403798 0.95139548 0.86730303 0.74346683\n",
      " 1.19929681 1.21842795 0.8713602  1.2445171  1.0759613  0.65174411\n",
      " 0.74541069 1.17600143 1.1722624  0.53337497 1.04746513 1.0088143\n",
      " 0.44949917 1.00203312 0.50991957 1.28716014 1.4251063  1.0886491\n",
      " 0.78291264 0.0625862  1.26680876 0.97422464 0.58471623 1.29140365\n",
      " 1.0886491  0.98642507 1.40251405 0.46486139 0.61751036 1.44410757\n",
      " 0.62462387 0.59111552 1.15172765 0.09496234 1.09800061 0.17137499\n",
      " 1.57234751 1.44702128 0.68664789 1.04538008 1.5956782  0.99416152\n",
      " 0.93703604 1.30912539 0.82760009 0.97152391 0.54136268 0.82366199\n",
      " 1.34899841 0.71108193 1.4259359  0.52708618 0.93703604 1.26916083\n",
      " 0.59351273 0.7443142  1.08167207 1.73405453 0.52708618 0.81665644\n",
      " 1.5848855  1.13859771 1.06594028 1.00715535 1.24585475 1.1132462\n",
      " 1.15875761 1.46274518 0.84557017 0.82933346 0.69569332 0.86431779\n",
      " 1.28019222 0.95969338 1.12529897 1.02558755 0.64407206 0.71727363\n",
      " 0.57186646]\n",
      "[1.2938894  1.10699679 1.44686304 1.08645683 1.04373245 0.99761348\n",
      " 1.00636739 1.28035763 0.70904804 1.28116819 0.64311082 0.83119296\n",
      " 1.08351608 0.60360367 1.03438416 1.02654586 0.92783775 0.79713592\n",
      " 1.10051608 0.83131488 1.10080791 0.82705543 1.33400744 1.30148357\n",
      " 0.91850759 1.29611907 0.6775619  1.25769518 1.19567477 0.79143362\n",
      " 0.88985732 0.9736558  0.80918607 0.54237661 1.20345093 0.71943569\n",
      " 1.03003968]\n",
      "[1.06796016 1.02695165 1.15566337 1.01615291 0.77629526 0.85154101\n",
      " 1.10543565]\n",
      "[0.89236422 1.00773618 1.01968183 1.04102655 1.17057532 0.86861589]\n",
      "[0.70888649 1.28875995 0.97248035 0.87786429 1.17199434 0.81909697\n",
      " 0.85751998 1.13100509 0.87621366 1.26185074 1.19561456 1.15726447\n",
      " 0.99042568 0.60084915 1.17366397 1.12915942 0.39813736 0.82773783\n",
      " 1.46861391 1.0928618  1.        ]\n",
      "[1.05450325 1.14247472 1.27471251 1.33700816 0.93847306 0.88370416\n",
      " 1.08243833 0.84796328 0.66467103 0.98437441 0.84921763 0.88120093\n",
      " 1.28639163 1.18922878 0.58074329 0.90219524 1.37004499 0.73065461]\n",
      "[1.06836048 0.93229    1.26588438 1.12079249 0.80082708 0.74414269\n",
      " 0.90700589 1.06443315 1.25527281 1.07734469 1.00867775 0.73686379\n",
      " 1.32585847 0.98881056 0.70343576]\n",
      "[1.]\n",
      "[1.18255336 1.38311386 1.31741344 0.87075858 0.84659723 0.89918476\n",
      " 0.75230845 0.74807033]\n",
      "[0.75279468 1.20998586 0.55729123 0.69043515 0.97242288 0.73802265\n",
      " 1.04556674 0.70120846 1.31690349 0.90212818 1.29522978 1.02218939\n",
      " 1.0176434  1.0493082  1.21301901 1.34225255 1.31595751 0.85764084]\n",
      "[1.01243862 0.87983298 1.1077284 ]\n",
      "[0.93128686 0.91516357 0.8858935  1.15790892 1.10974716]\n"
     ]
    }
   ],
   "source": [
    "for sentences in all_tokenized_sentences:\n",
    "\n",
    "    lxr = LexRank(sentences)\n",
    "\n",
    "    scores_cont = lxr.rank_sentences(\n",
    "        sentences,\n",
    "        threshold=None,\n",
    "        fast_power_method=True,\n",
    "    )\n",
    "\n",
    "    print(scores_cont)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Regional flu activity is defined as increased flu-like activity or flu outbreaks in at least two (but fewer than half) of the regions in a state with recent laboratory evidence of flu in those regions.', 'The first report of regional flu activity came from the southeastern United States during the first week of November.']\n",
      "['Flu activity increased during late December, peaked in mid-February, and decreased through the end of the flu season on May 19.', 'Nationally, low levels of flu activity were reported during October through mid-December.']\n",
      "['The severity of a flu season can be judged according to a variety of criteria, such as the following:\\\\nThe geographic extent of influenza in the U.S. and within each state;\\\\nThe proportion of influenza laboratory tests that are positive;\\\\nThe proportion of visits to physicians for influenza-like illness;\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of influenza-associated deaths among children; and\\\\nThe influenza-associated hospitalization rate among children.\\\\nA flu season�s severity is determined by comparing these measures with previous seasons.', 'The overall health impact (e.g., infections, hospitalizations and deaths) of a flu season varies from year to year.']\n",
      "['From October 1, 2006 to May 19, 2007, widespread** flu activity was reported in a total of 41 states across all regions of the country.', 'Influenza viruses were identified in all states.']\n",
      "['Although the timing of peak activity varies from year to year, peak activity usually occurs sometime during December through March.', 'During the past 31 years, flu activity in the United States has peaked in February 45 percent of the time.']\n",
      "['Estimates of flu-associated deaths are made by modeling death certificate data from the National Center for Health Statistics and from CDC influenza virus surveillance data.', 'This system collects information each week on the total number of death certificates filed in each of the 122 participating cities and the number of death certificates with pneumonia or influenza listed as a cause of death.']\n",
      "['However, beginning in early March and continuing through May, influenza A (H3) viruses were reported more frequently than influenza A (H1) viruses.', 'A particular subtype*** of influenza A called influenza A (H1) predominated during most of the season.']\n",
      "['Overall for the 2006-07 season, 24 percent of H3N2 viruses were well matched to the vaccine strain.', 'However, the proportion of H3N2 viruses similar to the H3N2 vaccine component declined as the season progressed.']\n",
      "['The number of flu-associated deaths among children reported during the 2006-07 flu season can be found in the', 'However, CDC first asked for flu deaths in children to be reported to CDC during the 2003-04 season.']\n",
      "['Children with asthma or other conditions should get the flu shot instead of the nasal spray.', 'The nasal spray vaccine is approved for healthy children 5 years of age and older.']\n",
      "['In January 2007, the Council of State and Territorial Epidemiologists voted to add human infections with novel influenza A viruses to the list of nationally notifiable diseases and conditions reportable to the National Notifiable Disease Surveillance System.', 'Novel influenza A viruses are viruses that are found in humans but are not ordinary human subtypes (many novel flu viruses originate from animals, such as birds or pigs), or those that cannot be subtyped by standard methods.']\n",
      "['Early detection and timely reporting of human infections with novel influenza A viruses will allow for rapid assessment of the situation and early implementation of the appropriate public health responses.', 'Because very few people have antibodies against novel influenza viruses, if a novel influenza virus infects a person and is then able to spread easily from one person to another person, a global epidemic, also know as a pandemic could begin.']\n",
      "['When compared with the previous three seasons, the 2007-2008 season was similar in severity to the 2004-2005 flu season in terms of the percentage of deaths due to pneumonia and flu, pediatric hospitalization rates, and the percentage of visits to outpatient clinics for flu-like illness.', 'A greater proportion of deaths associated with influenza illness and slightly higher rates of influenza-related hospitalizations in children 0-4 years occurred during the 2007-2008 U.S. flu season than was measured during each of the previous three seasons.']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe level of reported activity within each state;\\\\nThe proportion of influenza laboratory tests that are positive;\\\\nThe proportion of visits to physicians for influenza-like illness;\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of influenza-associated deaths among children; and\\\\nThe influenza-associated hospitalization rate among children', 'The overall health impact (e.g., infections, hospitalizations and deaths) of a flu season varies from year to year.']\n",
      "['In 16 of the past 26 years, the U.S. flu season has peaked in February or later, making this year pretty typical in terms of the timing of the peak.', 'Flu activity in the United States typically peaks between December and March, and the timing of peak activity changes from year to year.']\n",
      "['In February, when the flu season peaked, widespread* flu activity was reported in all 50 states across all regions of the country.\\\\n*Widespread flu activity is defined as increased flu-like activity or flu outbreaks in at least half of the regions in a state with recent laboratory evidence of flu in the state.', 'Flu viruses were identified in all states.']\n",
      "['Flu A viruses are subtyped in public health laboratories, such as state department of health laboratories and CDC Influenza Division laboratories.', 'Overall, for the 2007-2008 U.S. flu season, influenza A (H3N2) viruses were most commonly reported.\\\\n* Subtyping is the process of identifying an influenza A virus by its genetic and antigenic (biological) properties to determine if it is an influenza A (H3N2) or influenza A (H1N1) virus.']\n",
      "['At the time the vaccine virus selection decision was made, is was not yet clear that B/Yamagata viruses would become the predominant B viruses circulating in the United States this season.', 'For this reason, there is always the possibility of a less than optimal match between viruses in the vaccine and circulating viruses.']\n",
      "['For these reasons, even during seasons when there is a less than ideal match, CDC continues to recommend influenza vaccination.', 'In addition, it�s important to remember that the influenza vaccine contains three virus strains so that even when there is a less than ideal match or lower effectiveness against one strain, the vaccine may protect against the other two viruses.']\n",
      "['The United States experienced its first wave of 2009 H1N1 activity in the spring of 2009, followed by a second, larger wave of 2009 H1N1 activity in the fall and winter, during typical �flu season� time for the U.S. For information about 2009 H1N1 flu, visit the CDC 2009 H1N1 Flu website.', 'This virus caused the first influenza pandemic (global outbreak of disease caused by a novel influenza virus) in more than 40 years.']\n",
      "['(See�graph of peak influenza activity by month in the United States from 1976-2009.)', 'By the middle of May, no states were reporting widespread or regional influenza activity and most states were reporting sporadic or no flu activity.']\n",
      "['Additional information about severity of the 2009-2010 season can be found in the�MMWR�article', 'In fact, an estimated 80% of adult hospitalizations and 65% of child hospitalizations related to 2009 H1N1 occurred in people with one or more underlying medical conditions1.']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe number and proportion of flu laboratory tests that are positive;\\\\nThe proportion of visits to physicians for influenza-like illness (ILI);\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of flu-associated deaths among children; and\\\\nThe flu-associated hospitalization rate among children and adults.\\\\nA season�s severity is determined by assessing several of these measures and by comparing them with previous seasons.', 'The overall health impact (e.g., illnessess, hospitalizations and deaths) of a flu season varies from year to year.']\n",
      "['The vaccine may be somewhat less effective in elderly persons and very young children, but vaccination can still prevent serious complications from the flu.', 'Such protection is possible because antibodies made in response to the vaccine can provide some protection (called cross-protection) against different, but related strains of influenza viruses.']\n",
      "['Every year CDC carries out evaluations and collaborates with outside partners to assess the effectiveness of seasonal flu vaccines.']\n",
      "['Because of these factors, there is always the possibility of a less than optimal match between circulating flu viruses and the viruses in the seasonal flu vaccine.', '(For more information about the seasonal flu vaccine virus selection process, visit�Selecting the Viruses in the Influenza (Flu) Vaccine.)']\n",
      "['2009 H1N1 was by far the dominant virus in circulation last season, and the 2009 H1N1 vaccine was a very good match; 99.5% of the 2009 H1N1 virus specimens tested during the season were related to the virus used to develop the 2009 H1N1 vaccine.\\\\nThe 2010-2011 seasonal flu vaccine will protect against the 2009 H1N1 virus and 2 other flu viruses.', 'Therefore, a second flu vaccine was created to protect against the new flu virus.']\n",
      "['CDC also worked with the state public health departments and the World Health Organization to collect additional information on antiviral resistance in the United States and worldwide.', 'By the end of the 2009-2010 season, almost all (98.9%) of the 2009 H1N1 influenza viruses tested for antiviral resistance at CDC were susceptible to oseltamivir (Tamiflu�), and all of the viruses tested were susceptible to zanamivir (Relenza�).']\n",
      "['Because a certain age group may be hit harder by one type of influenza virus than another (for example, the 2009 H1N1 virus has disproportionately affected people younger than 65 years of age than those older than 65 whereas H3N2 virus often affects those older than 65 years), the 2010-2011 influenza season had a substantial health effect on every age group.\\\\nFlu seasons are unpredictable in a number of ways, including when they begin, how severe they are, how long they last, which viruses will spread, and whether the viruses in the vaccine match flu viruses that are circulating.\\\\nAdditional information about flu activity during the 2010-2011 season can be found in the MMWR article', 'In comparison to the last three seasons, the 2010-2011 influenza season was less severe than both the pandemic year (2009-2010) and the 2007-2008 season, but more severe than the 2008-2009 influenza season, as determined by the percentage of deaths resulting from pneumonia or influenza, the number of influenza-associated pediatric deaths reported, adult and pediatric hospitalization rates, and the percentage of visits to outpatient clinics for influenza-like illness (ILI).\\\\nOverall, during the 2010-2011 influenza season, the most commonly reported viruses were influenza A (H3N2), but 2009 influenza A (H1N1) viruses and influenza B viruses circulated as well.']\n",
      "['Widespread flu activity is defined as increased ILI or flu outbreaks and recent laboratory-confirmed flu in at least half of the regions in a state with recent laboratory evidence of flu in the state.', 'The peak number of states reporting widespread or regional activity during the previous three seasons has ranged from 49 to 50 states.\\\\n*Regional activity is defined as increased ILI or flu outbreaks and recent laboratory-confirmed flu in at least two but less than half of the regions in a state with recent laboratory evidence of flu in those regions.']\n",
      "['Additional information about severity of the 2010-2011 season can be found in the MMWR article', 'Overall, the 2010-2011 season was less severe than the 2009-2010 pandemic season and the 2007-2008 season, but more severe than the 2008-2009 season.']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe number and proportion of flu laboratory tests that are positive;\\\\nThe proportion of visits to physicians for influenza-like illness (ILI);\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of flu-associated deaths among children; and\\\\nThe flu-associated hospitalization rate among children and adults.\\\\nA season�s severity is determined by assessing several of these measures and by comparing them with previous seasons.', 'The overall health impact (e.g., illnesses, hospitalizations and deaths) of a flu season varies from year to year.']\n",
      "['Influenza A viruses are subtyped in public health laboratories, such as state department of health laboratories and CDC Influenza Division laboratories.', 'Overall, however, influenza A (H3N2) viruses were most commonly reported during the 2010-2011 flu season in the United States.\\\\n* Subtyping is the process of identifying an influenza A virus by its genetic and antigenic (biological) properties to determine if it is an influenza A (H3N2) or influenza A (H1N1) virus.']\n",
      "['In healthy adults younger than 65 years of age, the flu vaccine can also prevent lost work days, and keep you from having to see the doctor or using unnecessary antibiotics.', 'Lower effectiveness is expected in years when the match between circulating and vaccine viruses are suboptimal.']\n",
      "['In addition, CDC conducts special studies targeted at answering more specific questions, such as the effectiveness of inactivated vaccine in preventing laboratory-confirmed influenza hospitalizations among older U.S. residents.', 'CDC is currently conducting annual vaccine effectiveness studies among persons of all age groups recommended for annual vaccination (i.e., all aged 6 months and older).']\n",
      "['Because of these factors, there is always the possibility of a less than optimal match between circulating flu viruses and the viruses in the seasonal flu vaccine.', '(For more information about the seasonal flu vaccine virus selection process, visit .)']\n",
      "['CDC also worked with the state public health departments and the World Health Organization to collect additional information on antiviral resistance in the United States and worldwide.', 'Samples of viruses collected from around the United States and the world are studied to determine if they are resistant to any of the four FDA-approved influenza antiviral drugs.\\\\nCDC routinely collects viruses through a domestic and global surveillance system to monitor for changes in influenza viruses.']\n",
      "['Novel influenza A virus infections include all human infections with influenza A viruses that are different from currently circulating human influenza H1 and H3 viruses.', 'More information on influenza surveillance in the United States can be found on CDC�s influenza website.']\n",
      "['The season began late and was mild compared to most previous seasons for which surveillance data is available.\\\\nFlu seasons are unpredictable in a number of ways, including when they begin, how severe they are, how long they last, which viruses will spread, and whether the viruses in the vaccine match flu viruses that are circulating.', 'In comparison to other seasons, the 2011-2012 season set a new record for the lowest and shortest peak of influenza-like illness.']\n",
      "['(A more detailed description of influenza-like illness surveillance in the United States is available at Overview of Influenza Surveillance in the United States.)', 'In terms of ILI, this not only the shortest time at or above baseline, but it�s also the lowest �peak� ever recorded.']\n",
      "['The overall rate for all ages was lower in 2011-2012 (8.6 per 100,000) than in 2010-2011 season (21.3 per 100,000); age-group specific rates were also lower in 2011-2012 than in the previous year.\\\\nPercentage of visits to outpatient clinics for influenza-like illness\\\\nThe graph below compares ILI from five different seasons, including the 2011-2012 season, the 2009 H1N1 pandemic season, a �moderately severe� flu season (2007-2008), and a �moderate� season (2002-03).', 'Since 2004 the number of pediatric deaths has ranged from a low of 37 deaths during the 2011-2012 season, to a high of 288 deaths reported during the 2009-2010 season, which included pediatric deaths occurring during the 2009 H1N1 pandemic.\\\\nRates of influenza-associated hospitalizations\\\\nDuring the 2011-2012 season, the highest rates of hospitalizations were in people 65 years and older (30 per 100,000) and in children 0-4 years old (14 per 100,000).']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of flu-associated deaths among children;\\\\nThe proportion of visits to physicians for ILI;\\\\nThe flu-associated hospitalization rate among children and adults; and\\\\nThe number and proportion of flu laboratory tests that are positive.\\\\nA season�s severity is determined by assessing several of these measures and by comparing them with previous seasons.', 'The overall health impact (e.g., illnesses, hospitalizations and deaths) of a flu season varies from year to year.']\n",
      "['Most of the viruses tested this season were well matched to the vaccine viruses (the viruses the 2011-2012 seasonal influenza vaccine is designed to protect against).', 'Over the course of the season, predominant viruses varied from region to region and between states, but nationally, influenza A (H3N2) influenza viruses predominated.']\n",
      "['A more detailed report of the final 2011-2012 flu season VE estimates is available in an article published in Clinical Infectious Diseases.', 'These results show moderate effectiveness against circulating influenza viruses, and are similar to the preliminary VE estimate reported earlier in the 2011-2012 season (52%, 95% CI, 38% to 63%).']\n",
      "['The public health community and the federal government are investing in and supporting the development of new and improved influenza vaccines.', 'In the meantime, influenza vaccine is the best tool we have to protect as many people as possible against influenza.']\n",
      "['These differences can make it difficult to compare one study�s results with another�s.\\\\nWhile determining how well a flu vaccine works is challenging, in general, recent studies have supported the conclusion that influenza vaccination benefits public health, especially when the viruses in the vaccine and circulating viruses are well-matched.', 'Study results about how well a flu vaccine works can vary based on study design, outcome(s) measured, population studied and the season in which the vaccine was studied.']\n",
      "['Similar studies are being done in Australia, Canada and Europe.', 'To assess how well the vaccine works across different age groups, CDC�s studies of vaccine effects have included all people aged 6 months and older recommended at that time for an annual influenza vaccination.']\n",
      "['All of the influenza B viruses tested were susceptible to oseltamivir and zanamivir.\\\\nHigh levels of resistance to the adamantanes (amantadine and rimantadine) persisted among pH1N1 and influenza A (H3N2) viruses currently circulating globally.', 'The information collected assisted in making informed public health policy recommendations.\\\\nBy the end of the 2011-2012 season, almost all (98.6%) of the 2009 H1N1 influenza viruses tested for antiviral resistance at CDC were susceptible to oseltamivir (Tamiflu�), and all 2009 H1N1 influenza viruses tested were susceptible to zanamivir (Relenza �).']\n",
      "['One case was in a person who reported close contact with swine preceding symptom onset; both patients are fully recovered.\\\\nSince July 2012, there have been outbreaks of H3N2 variant viruses with the matrix (M) gene from the 2009 H1N1 pandemic virus in multiple U.S. states.', 'In addition, two other novel viruses were identified during the 2011�12 season: one case of influenza A (H1N2) variant (H1N2v) was identified in Minnesota, and one case of influenza A (H1N1) variant (H1N1v) was identified in Wisconsin.']\n",
      "['Influenza-like-illness rose quickly to well above the baseline of expected activity and remained elevated for 15 consecutive weeks, making this season slightly longer than average.\\\\nAdditional information about flu activity during the 2012-2013 season can be found in 2012-2013 Flu Season Draws to a Close and in the MMWR article Influenza Activity � United States, 2012-13 Season, and Composition of the 2013-14 Influenza Vaccine.', 'This season had a somewhat early increase in flu activity through November and December, with a peak in late December.']\n",
      "['In contrast, the peak percentage of outpatient visits for ILI during the previous influenza season (2011�12) was 2.4% (which occurred in mid-March).\\\\nFluView interactive provides visualizations of influenza information collected by CDC�s monitoring systems.', 'Flu activity most commonly peaks in the United States between December and February.\\\\nThis was one of the highest reported peaks since the system began reporting in its current format in 1997.']\n",
      "['This was the highest recorded P & I in nearly a decade, but it is comparable to recorded percentages for past severe seasons, including 2003-2004 when P&I reached 10 percent.', 'Pneumonia and influenza diagnoses (P & I) first rose above the epidemic threshold the week ending January 5, 2013 and peaked the week ending January 19, 2013 at 9.9 percent.']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe number and proportion of respiratory specimens that are influenza-positive;\\\\nThe proportion of visits to physicians for ILI;\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of flu-associated deaths among children; and\\\\nFlu-associated hospitalization rates.\\\\nA season�s severity is determined by assessing several of these measures and by comparing available data with previous seasons.', 'The overall health impact (e.g., illnesses, hospitalizations and deaths) of a flu season varies from year to year.']\n",
      "['Over the course of the entire 2012�2013 season, influenza A (H3N2) viruses predominated nationally, followed by influenza B viruses; 2009 influenza A (H1N1) viruses were identified less frequently.\\\\nInfluenza A viruses predominated until the end of February 2013, after which influenza B viruses were detected more often.\\\\nThe relative proportion of each type and subtype varied by geographic region and by week.']\n",
      "['While influenza can be serious for everyone, hospitalization data indicate people 65 and older were more severely impacted by the 2012-2013 flu season, relative to other age groups.\\\\nThis is consistent with previous observations of the burden of flu illness in the elderly: data from statistical modeling studies looking at flu seasons from 1979 to 2001 estimate that as many as 60% of flu-related hospitalizations occur among people 65 and older.']\n",
      "['Both infections occurred in children, one of which had known exposure to swine.', 'One was reported from Minnesota, and the other from Iowa.']\n",
      "['The information assists CDC in making informed recommendations for treatment and prevention of influenza in the United States.', 'CDC also works with the state public health departments and World Health Organization to collect additional information on antiviral resistance in the United States and worldwide.']\n",
      "['More information about flu activity during the 2013-14 season can be found in FluView and the MMWR report', 'Flu activity peaked during the week ending December 28, 2013 for the 2013-2014 season and began a downward trend in early January.\\\\nSeverity indicators usually lag behind ILI.']\n",
      "['After several recent influenza A (H3N2)�predominant seasons, 2013-14 was the first pH1N1�predominant season since the 2009 pH1N1 pandemic.', '2009 H1N1 viruses predominated overall during the 2013-14 flu season, though influenza B viruses became the predominant virus nationally later in the season and caused an increase in influenza-like-illness in parts of the northeast especially.']\n",
      "['These indicators underscore the impact that seasonal flu had in the United States, particularly on people less than 65 years of age.', 'Hospitalization rates among those aged 50 to 64 years were higher than those seen during the 2009 pandemic and in any year since.']\n",
      "['(This excludes the 2009 pandemic, when 348 pediatric deaths were reported to CDC during April 15, 2009, through October 2, 2010.)', 'More information about reported pediatric deaths is available at FluView: Influenza-Associated Pediatric Mortality.\\\\nSince influenza-associated pediatric mortality became a nationally-notifiable condition during the 2004-2005 season, the total number of influenza-associated pediatric deaths had previously ranged from 35 to 171 per season.']\n",
      "['and go to the questions: �How does CDC present data on vaccine effectiveness� and �Why are confidence intervals important for understanding vaccine effectiveness?�)', ')\\\\n(For background information on understanding VE estimates and confidence intervals, see Vaccine Effectiveness � How Well Does the Flu Vaccine Work?']\n",
      "['In addition, CDC conducts special studies targeted at answering more specific questions, such as the effectiveness of inactivated vaccine in preventing laboratory-confirmed influenza hospitalizations among older U.S. residents.', 'CDC is currently conducting annual vaccine effectiveness studies among persons of all age groups recommended for annual vaccination (i.e., all aged 6 months and older).']\n",
      "['Vaccine for the 2014-2015 season will be available in late summer and in the fall.', 'All 2013-2014 seasonal flu vaccine has expired.']\n",
      "['As of late February, more than 134 million doses of flu vaccine had been delivered in the United States.\\\\nInformation about vaccine supply is available on the CDC influenza web site.', 'Information about the number of seasonal flu vaccine doses distributed this season is available at Seasonal Flu Vaccine & Total Doses Distributed.\\\\nIn May 2013, flu vaccine manufacturers projected about 138-145 million doses would be available for the U.S. market during the 2013-214 season.']\n",
      "['Other standard-dose quadrivalent shots are approved for people 3 years and older.\\\\nA standard dose quadrivalent flu vaccine, given as a nasal spray, which is approved for healthy* people 2 through 49 years of age\\\\n(*�Healthy� indicates persons who do not have an underlying medical condition that predisposes them to influenza complications.)', 'The following quadrivalent flu vaccines are available:\\\\nA standard-dose quadrivalent shot that can be given to children as young as 6 months of age.']\n",
      "['More information about influenza vaccines is available at Preventing Seasonal Flu With Vaccination.', 'Each year, these viruses are used to produce seasonal influenza vaccine.\\\\nThe 2013-2014 trivalent influenza vaccine was made from the following three viruses:\\\\nan A/California/7/2009 (H1N1)pdm09-like virus;\\\\nan A(H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011;\\\\na B/Massachusetts/2/2012-like virus.\\\\nIt is recommended that the quadrivalent vaccine containing two influenza B viruses include the above three viruses and a B/Brisbane/60/2008-like virus.\\\\nCDC did not recommend any one flu vaccine over another.']\n",
      "['This occurs every season.', 'CDC received reports of some people who became ill and tested positive for the flu even though they had been vaccinated.']\n",
      "['This is the recommended influenza B component of the 2013-2014 Northern Hemisphere quadrivalent influenza vaccine.', 'This is an influenza B component for the 2013-2014 Northern Hemisphere quadrivalent and trivalent influenza vaccines.\\\\nThe 112 (29.4%) other influenza B viruses belonged to the B/Victoria lineage of viruses, and were characterized as B/Brisbane/60/2008-like.']\n",
      "['The information collected will assist in making informed public health policy recommendations.', 'Additionally, CDC is working with the state public health departments and the World Health Organization to collect additional information on antiviral resistance in the United States and worldwide.']\n",
      "['Therefore, amantadine and rimantadine are not recommended for use this season.\\\\nCDC and its public health partners around the world are committed to informing the public of any significant increases in antiviral resistance among circulating influenza viruses.', 'No flu viruses tested were resistant to zanamivir (trade name Relenza).\\\\nHigh levels of resistance to the adamantanes (amantadine and rimantadine) persist among 2009 influenza A (H1N1) and A (H3N2) viruses (the adamantanes are not effective against influenza B viruses).']\n",
      "['CDC continues to work closely with its partners at the state level to monitor for antiviral resistant flu viruses this season.', 'CDC has worked with states where antiviral resistant flu viruses have been found to enhance surveillance for these viruses and to inform public health professionals of the latest information and recommendations.']\n",
      "['See 2014-2015 Flu Season Drawing to a Close for more information.', 'Over the previous 13 seasons, ILI was at or above baseline for 13 weeks on average, with a range of one week to 19 weeks.']\n",
      "['However, flu activity most often peaks in February and can last into May.\\\\nMore information about flu activity during the 2014-2015 season can be found in 2014-2015 Flu Season Drawing to a Close, FluView, and the MMWR report', 'The timing of flu is unpredictable and can vary in different parts of the country and from season to season.']\n",
      "['Based on available data from U.S. influenza surveillance systems that are monitored and reported on by CDC, the severity of a flu season is judged according to a variety of criteria, including:\\\\nThe number and proportion of respiratory specimens that are influenza-positive;\\\\nThe proportion of visits to healthcare providers that are due for ILI;\\\\nThe proportion of all deaths that are caused by pneumonia and influenza ;\\\\nThe number of flu-associated deaths among children; and\\\\nFlu-associated hospitalization rates.\\\\nCDC assesses the severity of a season by comparing the data from these measures with data from previous seasons.', 'The overall health impact (e.g., outpatient illnesses, hospitalizations and deaths) of a flu season varies from year to year.']\n",
      "['For more information, see Overview of Influenza Surveillance in the United States.\\\\nCDC also uses modeling studies to estimate numbers of flu-related deaths, but these studies apply only to past seasons and are not done each year.', 'Both of these systems track the proportion of death certificates processed that list pneumonia or influenza as the underlying or contributing cause of death of the total deaths reported.']\n",
      "['Some of the challenges in counting influenza-associated deaths include the following: the sheer volume of deaths to be counted; the fact that not everyone that dies with an influenza-like illness is tested for influenza; and the fact that influenza-associated deaths are often a result of complications secondary to influenza and underlying medical problems, and this may be difficult to sort out.', 'For more information']\n",
      "['Influenza B viruses predominated from the week ending February 28, 2015 (week 8) through the week ending May 23, 2015 (week 20).\\\\nThe relative proportion of each type and subtype varied by geographic region and by week.', 'Overall, influenza A (H3N2) viruses predominated nationally, followed by influenza B viruses; influenza A (H1N1)pdm09 viruses were identified less frequently.\\\\nInfluenza A viruses were more commonly detected until late February 2015, after which there was substantial influenza B activity.']\n",
      "['See Estimated Influenza Illnesses and Hospitalizations Averted by Vaccination � United States, 2014-15 Influenza Season for more information.\\\\nThese data are consistent with observations of the burden of flu illness in the elderly from previous years: data from statistical modeling studies looking at flu seasons from 1979 to 2001 estimate that as many as 60% of flu-related hospitalizations occurred among people 65 years and older.', 'CDC estimates that the overall burden of influenza disease estimated across all age groups was 40 million flu illnesses, 19 million flu-associated medical visits, and 970,000 flu-associated hospitalizations.']\n",
      "['As of February 1, 2016, a total of 148 laboratory-confirmed, influenza-associated pediatric deaths occurring during the 2014-2015 flu season were reported to CDC from 41 states and New York City.\\\\nSince influenza-associated pediatric mortality became a nationally-notifiable condition during the 2004-2005 season, the total number of influenza-associated pediatric deaths has ranged from 34 to 171.']\n",
      "['Human infections with H1N1v, H3N2v and H1N2v viruses have been detected in the United States.', 'The patient died from complications of the infection, and no ongoing human-to-human transmission was identified.\\\\nSwine flu viruses do not normally infect humans.']\n",
      "['Some seasonal flu vaccines were formulated to protect against four flu viruses (quadrivalent flu vaccines).', 'A number of different manufacturers produced trivalent (three component) influenza vaccines for the U.S. market, including intramuscular (IM), intradermal, and nasal spray vaccines.']\n",
      "['More information on this vote is available at the CDC Newsroom.', 'The ACIP recommendations must be approved by the CDC Director at which point they are published in the MMWR and become CDC policy.']\n",
      "['As of February 2015, approximately 147.8 million doses of flu vaccine were distributed.', 'Of those projected doses, manufacturers estimated that 76 million doses would be quadrivalent flu vaccine.']\n",
      "['Vaccines that give protection against four viruses are called quadrivalent vaccines.', 'In addition to the above three, quadrivalent vaccines were made to protect against an B/Brisbane/60/2008-like virus.\\\\nVaccines that give protection against three viruses are called trivalent vaccines.']\n",
      "['The adjusted VE estimate against influenza A (H3N2) viruses for all ages was 13%.\\\\nReduced protection against influenza A (H3N2) viruses for the 2014-2015 season was attributed to the fact that more than 80% of circulating influenza A (H3N2) viruses analyzed at CDC were different or �drifted� from the recommended influenza A (H3N2) vaccine virus.\\\\nThese vaccine effectiveness estimates were derived from data collected', 'CDC�s adjusted overall VE estimate against influenza A and B viruses for all ages was 23%.']\n",
      "['However, the vaccine worked well against about one-third of circulating influenza A (H3N2) viruses that were similar to the recommended vaccine virus and against influenza A (H1N1) and influenza B viruses.', 'This is probably why there was reduced vaccine effectiveness against those drifted influenza A (H3N2) viruses.']\n",
      "['At that time, only a very small number of these viruses had been found among the thousands of specimens that had been collected and tested and there was no way to predict that they would circulate widely.', 'The drifted influenza A (H3N2) viruses that circulated during the 2014-2015 season were first detected during routine surveillance testing in late March 2014, after World Health Organization (WHO) recommendations for the vaccine composition for the Northern Hemisphere formulation of the 2014-2015 vaccine were made (in mid-February).']\n",
      "['The information collected will assist in making informed recommendations regarding use of antiviral drugs to treat influenza.', 'Additionally, CDC works with the state public health departments and the World Health Organization to collect additional information on antiviral resistance in the United States and worldwide.']\n",
      "['During the 2014-2015 season, CDC completed multiple studies on the effectiveness of both the flu shot and the nasal-spray flu vaccine.', 'These studies measured vaccine effectiveness in preventing laboratory-confirmed influenza among persons 6 months of age and older.']\n",
      "['While there were reports of severe flu illnesses and deaths, overall the 2015-2016 season was milder than the previous three seasons.', 'This is the virus that emerged in 2009 to cause a pandemic and that caused severe illness in some children & young-and middle-aged adults.']\n",
      "['Over the last 18 seasons (including the 2015-2016 season), only three seasons have peaked during March (2015-2016, 2011-2012 and 2005-2006).', 'This is one of the later season peaks on record.']\n",
      "['CDC usedtwo flu surveillance systemsto monitor relative levels of flu-associated deaths: mortality data from the National Center for Health Statistics and the 122 Cities Mortality Reporting System.', 'Based on data from CDC’s National Center for Health Statistics Mortality Surveillance System, the proportion of deaths attributed to P&I was at or slightly above the epidemic threshold for three consecutive weeks from the week ending January 2, 2016, through the week ending January 16, 2016 (weeks 52-2) and again for four consecutive weeks from the week ending February 27, 2016, through the week ending March 19, 2016 (weeks 8-11).']\n",
      "['(This excludes the 2009 pandemic, when 358 pediatric deaths were reported to CDC during April 15, 2009, through October 2, 2010.)', 'Since influenza-associated pediatric mortality became a nationally-notifiable condition during the 2004-2005 season, the total number of influenza-associated pediatric deaths has ranged from 37 to 171.']\n",
      "['Influenza A(H3N2) viruses were more commonly identified from October through early December, and influenza B viruses were more commonly identified from mid-April through mid-May.', 'However, influenza A (H3N2), A(H1N1)pdm09 and influenza B viruses from both lineages were detected last season.']\n",
      "['Top of Page', 'There was no evidence of human-to-human transmission associated with any of these reports.']\n",
      "['More information about flu vaccine supply is available atSeasonal Influenza Vaccine & Total Doses Distributed.', 'As of February 26, 2016, manufacturers reported having shipped approximately 146.4 million doses of flu vaccine.']\n",
      "['This data is consistent with VE observed during previous seasons when vaccine viruses and circulating viruses were similar.', 'The overall VE against A(H1N1)pdm09 was 41% and the overall VE against influenza B was 55%.']\n",
      "['Laboratory data show that most of the circulating flu viruses were like the viruses recommended for the 2015-2016 influenza vaccines.', 'Yes.']\n",
      "['High levels of resistance to the adamantanes (amantadine and rimantadine) persisted among influenza A viruses.', 'All influenza A(H1N1)pdm09 viruses tested were susceptible to zanamivir.']\n",
      "['Yes.', 'Top of Page']\n",
      "['Morbidity and Mortality Weekly Reports (MMWR) CDC Flu Reports & Spotlights']\n",
      "['This page summarizes information for the 2016-2017 flu season.', 'Increasing the number of people who get vaccinated each year helps to protect more people, including older people, very young children, pregnant women and people with certain health conditions who are more vulnerable to serious flu complications.']\n",
      "['As of a flu activity update published in theMorbidity and Mortality Weekly Report on February 17, 2017, flu activity during the 2016-2017 season had been moderate, with influenza A (H3N2) viruses predominating and severity indicators within the range of what has been seen during previous seasons that were H3N2-predominant.', 'For more information, seeOverview of Influenza Surveillance in the United States, “Mortality Surveillance.” CDC also uses modeling studies to estimate numbers of flu-related deaths, but these studies apply only to past seasons and are not done each year.']\n",
      "['Children in this age group who are getting vaccinated for the first time will need two doses of flu vaccine, spaced at least 28 days apart.', 'Also, if you have a loved one who is at high risk of flu complications and they develop flu symptoms, encourage them to get a medical evaluation for possible treatment with flu antiviral drugs.']\n",
      "['Flu vaccine is produced by private manufacturers, so the timing of vaccine availability depends on when production is completed.', 'As such, there may be some supply of FluMist Quadrivalent on the U.S. market during the 2016-2017 season.']\n",
      "['Treating high risk people or people who are very sick with flu with antiviral drugs is very important.', 'People athigh riskof serious flucomplications(such as children younger than 5 years, adults 65 years of age and older, pregnant women, people with certain medical conditions, and residents of nursing homes and other long-term care facilities) and people who are very sick with flu (such as those hospitalized because of flu) should get treatment with antiviral drugs as early as possible after illness begins.']\n",
      "['The information collected will assist in making informed recommendations regarding use of antiviral drugs to treat influenza.', 'It’s important to note, however, that because testing practices and the number of participating public health laboratories can change from year to year; it is not always appropriate to determine the relative severity of flu seasons by comparing the number of positive specimens across seasons.']\n",
      "['Parotitis after flu appears to occur in people of all ages but mostly in school-aged children and more commonly in males.', 'Acute viral parotitis is not a common symptom of flu virus infection and is much more commonly seen following infection with the mumps virus.']\n",
      "['The 2017-18 season was the first season to be classified as a high severity across all age groups.', 'In 2017, CDC began usingnew methodologyto classify seasonal severity and applied the methodology to the 2003-2004 through 2016-2017 seasons.']\n",
      "['Influenza-like illness (ILI) was at or above the national baseline for 19 weeks, making the 2017-2018 season one of the longest in recent years.', 'During the 2017-2018 season, influenza-like-illness (ILI) activity began to increase in November, reaching an extended period of high activity during January and February nationally, and remained elevated through the end of March.']\n",
      "['For more information, seeOverview of Influenza Surveillance in the United States, “Mortality Surveillance.”', 'For more information, seeEstimating Seasonal Influenza-Associated Deaths in the United Statesand CDC’sDisease Burden of Influenzapage.']\n",
      "['Since flu-associated deaths in children became a nationally notifiable condition in 2004, the total number of flu-associated deaths among children during one season has ranged from 37 (during the 2011-2012 season) to 186 (during the 2017-18 season, as of April 19, 2019); this excludes the 2009 pandemic, when 358 pediatric deaths from April 15, 2009 through October 2, 2010 were reported to CDC.', 'This number exceeds the previously highest number of flu-associated deaths in children reported during a regular flu season (171 during the 2012-2013 season).']\n",
      "['Estimates on the total number of flu-related hospitalizations during 2017-2018 will be available in fall 2018.', '(For more information on these estimates, seeCDC’s Disease Burden of Influenza page.)']\n",
      "['However, influenza B viruses became more commonly reported than influenza A viruses in early March 2018 through May 2018.', 'Influenza A(H3N2) viruses predominated overall during the 2017-2018 season.']\n",
      "['More information about flu vaccine supply is available atSeasonal Influenza Vaccine Supply & Distribution.', 'As of February 23, 2018, manufacturers reported having shipped approximately 155.3 million doses of flu vaccine; a record number of flu vaccine doses distributed.']\n",
      "['Influenza vaccination also has been shown to reduce the risk of flu death in\\xa0children.', 'The overall vaccine effectiveness (VE) of the 2017-2018 flu vaccine against both influenza A and B viruses is estimated to be 40%.']\n",
      "['The majority of the influenza viruses collected from the United States during the 2017-2018 flu season were characterized antigenically and genetically as being similar to the cell-grown reference viruses representing the 2017–18 Northern Hemisphere influenza vaccine viruses.', 'Yes.']\n",
      "['These results indicate that these antiviral drugs continue to be recommended treatment options for illness caused by currently circulating influenza viruses.', 'While the majority of the tested viruses showed susceptibility to the antiviral drugs, 11 (1.0%) H1N1pdm09 viruses were resistant to both oseltamivir and peramivir, but were sensitive to zanamivir.']\n",
      "['Baloxavir is approved for the treatment of acute uncomplicated flu in people 12 years and older who have had flu symptoms for less than 48 hours.', 'When these indicators rise and remain elevated for a number of consecutive weeks, “flu season” is said to have begun.']\n",
      "['Based on data from past flu seasons, CDC researchers used key flu indicator data to develop intensity thresholds (ITs) to classify the severity of flu seasons.', 'In 2017, CDC adopted and outlined a new methodology for determining flu season severity.']\n",
      "['Options this season include: There is a table\\xa0showing all flu vaccines that are FDA-approved for use in the United States during the 2019-2020 season.', 'The most helpful data for this is the antigenic characterization data, which are updated weekly in FluView.']\n",
      "['Children 6 months through 8 years of age who need 2 doses should receive their first dose as soon as possible after the vaccine becomes available to allow the second dose (which must be administered at least 4 weeks later) to be received by the end of October.', 'In trying to balance the need to get many people vaccinated before flu activity begins with concerns about potential waning of vaccine-induced immunity during the flu season, CDC and ACIP recommend that vaccination be offered by the end of October.']\n",
      "['There is no preferential recommendation for one flu vaccine over another.', 'While the use of cell-grown vaccine viruses and cell-based technology may offer the potential for better protection over traditional, egg-based flu vaccines because they result in vaccine viruses that are more similar to flu viruses in circulation, there are no vaccine effectiveness data to support this.']\n",
      "['The timing of flu is unpredictable and can vary in different parts of the country and from season to season.', 'What sort of flu season is expected this year?']\n",
      "['Why is the nasal spray being recommended as an option this year when it has been shown to not be effective in past flu seasons?', 'Since the 2018-2019 season, the manufacturer of nasal spray vaccine has used a new H1N1 vaccine virus in production.']\n",
      "['Another factor that can impact vaccine effectiveness, especially against influenza A(H3N2) viruses, are changes that can occur in vaccine viruses as they are grown in eggs, which is the\\xa0production method for most current flu vaccines.', 'One of the ways that helps CDC evaluate the match between flu vaccine viruses and circulating flu viruses is with a lab process called ‘genetic and\\xa0antigenic characterization’.']\n",
      "['Most people with flu have mild illness and do not need medical care or antiviral drugs.', 'Antiviral treatment as early as possible is also recommended for people who are very sick with flu (such as those with complicated, progressive illness or people hospitalized because of flu).']\n",
      "['The information collected will assist in making informed recommendations regarding use of antiviral drugs to treat flu.', 'What is CDC doing to monitor antiviral resistance in the United States during the 2019-2020 season?']\n",
      "['The number of flu vaccine doses distributed, vaccination coverage estimates for children, and vaccinations administered in retail pharmacies and doctor’s offices were updated weekly.', 'The dashboard included information on the number of influenza vaccine doses distributed in the United States, weekly flu vaccination coverage rates for children 6 months – 17 years old, monthly flu vaccination coverage rates among pregnant persons, and information on how many flu vaccines were administered in pharmacies and doctor’s offices.']\n",
      "['It is important to note that the actual number of flu-associated deaths in children is likely to be higher than what is reported by states to CDC because not all flu deaths in children are detected/reported.', 'To estimate the number of influenza-associated hospitalizations that occur in a flu season, CDC looks at how many in-hospital deaths are observed in the FluSurv-NET surveillance system.']\n",
      "['The A(H5N1) identification was the first positive test for avian influenza A(H5) virus in a human in the United States.', 'Six A(H1N2)v virus infections were identified (one each in California, Georgia, Michigan, Ohio, Oregon and Wisconsin); five A(H3N2)v virus infections were identified (one each in Michigan and Ohio, and three in West Virginia); and one A(H1)v virus infection was identified (Oklahoma).']\n",
      "['For more information, visit\\xa0Influenza Vaccine for the 2021-2022 Season | FDAexternal icon For the 2021-2022 flu season, there was no recommended preference for any one vaccine over another, and providers could administer any licensed, age-appropriate flu vaccine (IIV, RIV4, or LAIV4).', 'Compared with the Southern Hemisphere flu vaccine recommendation, this recommendation represented one update and that was to the influenza A(H3N2) component.']\n",
      "['In the past, vaccine effectiveness against H3N2 viruses has often been lower than against A(H1N1) and influenza B viruses.', 'Preliminary early-season vaccine effectiveness estimates from March 2022 suggested flu vaccines were providing no measurable protection against mild to moderate illness caused by the most common influenza A(H3N2) virus during the 2021-2022 flu season.']\n",
      "['Additional information about NIS-Flu methods and estimates from 2019-2020 season are available at FluVaxView.', 'Of note, because these estimates are based on data from nine integrated health care systems, they may not be representative of all pregnant people in the United States.']\n",
      "['More information on flu surveillance methodology and these updates is available online.', 'These improvements include more testing, new surveillance system components, and presenting more data at the state level and sub-state level.']\n",
      "['A couple of things are different for the 2023-2024 influenza (flu) season:']\n",
      "['Flu vaccination is often available at no or low cost to people who do not have insurance.', 'Although monitoring influenza-only coded deaths will underestimate the full impact of influenza mortality, this measure allows for tracking trends in the impact of influenza on mortality and is not as influenced by COVID-19 as the other two measures.']\n",
      "['CDC is not involved in regulatory decision-making, including for flu vaccines, but will make a recommendation on the use of flu vaccine for 2024-2025 season once VRBPAC has selected the viruses for inclusion in U.S. 2024-2025 flu vaccines.', 'B/Yamagata flu viruses have not circulated in the population since March 2020, so protection from trivalent and quadrivalent flu vaccines is expected to be similar.']\n",
      "['It is also possible to be sick with multiple flu viruses, like influenza A and B, at the same time.', 'This includes being sick with flu and COVID-19.']\n",
      "['It also shows the percentages of flu and COVID-19 coinfections as well as flu and RSV coinfections among people hospitalized with laboratory-confirmed influenza virus infection during this time period.', 'The table provides the total number of COVID-19 and flu coinfections as well as the total number of flu and RSV coinfections reported during this time frame among patients hospitalized with laboratory-confirmed influenza virus infection.']\n"
     ]
    }
   ],
   "source": [
    "for sentences in all_tokenized_sentences:\n",
    "\n",
    "    lxr = LexRank(sentences)\n",
    "\n",
    "    summary = lxr.get_summary(sentences, summary_size=2, threshold=0.05)\n",
    "    \n",
    "    print(summary)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "summaries = []\n",
    "\n",
    "for sentences in all_tokenized_sentences:\n",
    "    lxr = LexRank(sentences)\n",
    "    summary_cont = lxr.get_summary(sentences, summary_size=2, threshold=0.05)\n",
    "    \n",
    "    summaries.append(summary_cont[0] if summary_cont else None)\n",
    "\n",
    "content['Summary'] = summaries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Year</th>\n",
       "      <th>Topic</th>\n",
       "      <th>Content</th>\n",
       "      <th>Summary</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>When and where did the 2006-07 flu season start?</td>\n",
       "      <td>The first report of regional flu activity came...</td>\n",
       "      <td>Regional flu activity is defined as increased ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>How severe was the 2006-2007 flu season?</td>\n",
       "      <td>The 2006-07 flu season was generally mild comp...</td>\n",
       "      <td>Flu activity increased during late December, p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>What determines the severity of a flu season?</td>\n",
       "      <td>The overall health impact (e.g., infections, h...</td>\n",
       "      <td>The severity of a flu season can be judged acc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>Where did the most flu activity occur in the U...</td>\n",
       "      <td>Influenza viruses were identified in all state...</td>\n",
       "      <td>From October 1, 2006 to May 19, 2007, widespre...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2006-2007</td>\n",
       "      <td>When did the 2006-2007 flu season peak?</td>\n",
       "      <td>During the 2006-2007 season, flu activity in t...</td>\n",
       "      <td>Although the timing of peak activity varies fr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>136</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>Updates to the Advisory Committee on Immunizat...</td>\n",
       "      <td>A couple of things are different for the 2023-...</td>\n",
       "      <td>A couple of things are different for the 2023-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>Updates to U.S. Flu Surveillance Methods for t...</td>\n",
       "      <td>Starting with the 2023-2024 influenza season, ...</td>\n",
       "      <td>Flu vaccination is often available at no or lo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>138</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>B/Yamagata and Flu Vaccines Summary</td>\n",
       "      <td>Quadrivalent flu vaccines protect against four...</td>\n",
       "      <td>CDC is not involved in regulatory decision-mak...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>Coinfection: Getting More than One Respiratory...</td>\n",
       "      <td>It is possible to get sick with more than one ...</td>\n",
       "      <td>It is also possible to be sick with multiple f...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>2023-2024</td>\n",
       "      <td>Flu, RSV, and COVID-19 Coinfection Data: 2023-...</td>\n",
       "      <td>One way CDC collects data on coinfections with...</td>\n",
       "      <td>It also shows the percentages of flu and COVID...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>141 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          Year                                              Topic  \\\n",
       "0    2006-2007   When and where did the 2006-07 flu season start?   \n",
       "1    2006-2007           How severe was the 2006-2007 flu season?   \n",
       "2    2006-2007      What determines the severity of a flu season?   \n",
       "3    2006-2007  Where did the most flu activity occur in the U...   \n",
       "4    2006-2007            When did the 2006-2007 flu season peak?   \n",
       "..         ...                                                ...   \n",
       "136  2023-2024  Updates to the Advisory Committee on Immunizat...   \n",
       "137  2023-2024  Updates to U.S. Flu Surveillance Methods for t...   \n",
       "138  2023-2024                B/Yamagata and Flu Vaccines Summary   \n",
       "139  2023-2024  Coinfection: Getting More than One Respiratory...   \n",
       "140  2023-2024  Flu, RSV, and COVID-19 Coinfection Data: 2023-...   \n",
       "\n",
       "                                               Content  \\\n",
       "0    The first report of regional flu activity came...   \n",
       "1    The 2006-07 flu season was generally mild comp...   \n",
       "2    The overall health impact (e.g., infections, h...   \n",
       "3    Influenza viruses were identified in all state...   \n",
       "4    During the 2006-2007 season, flu activity in t...   \n",
       "..                                                 ...   \n",
       "136  A couple of things are different for the 2023-...   \n",
       "137  Starting with the 2023-2024 influenza season, ...   \n",
       "138  Quadrivalent flu vaccines protect against four...   \n",
       "139  It is possible to get sick with more than one ...   \n",
       "140  One way CDC collects data on coinfections with...   \n",
       "\n",
       "                                               Summary  \n",
       "0    Regional flu activity is defined as increased ...  \n",
       "1    Flu activity increased during late December, p...  \n",
       "2    The severity of a flu season can be judged acc...  \n",
       "3    From October 1, 2006 to May 19, 2007, widespre...  \n",
       "4    Although the timing of peak activity varies fr...  \n",
       "..                                                 ...  \n",
       "136  A couple of things are different for the 2023-...  \n",
       "137  Flu vaccination is often available at no or lo...  \n",
       "138  CDC is not involved in regulatory decision-mak...  \n",
       "139  It is also possible to be sick with multiple f...  \n",
       "140  It also shows the percentages of flu and COVID...  \n",
       "\n",
       "[141 rows x 4 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "content"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Save to CSV file"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "content.to_csv('data/flu_data_summary.csv', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Regional flu activity is defined as increased flu-like activity or flu outbreaks in at least two (but fewer than half) of the regions in a state with recent laboratory evidence of flu in those regions.']\n",
      "['For example, the proportion of all deaths associated with influenza illness was lower this season than the previous three flu seasons.']\n",
      "['The severity of a flu season can be judged according to a variety of criteria, such as the following:\\\\nThe geographic extent of influenza in the U.S. and within each state;\\\\nThe proportion of influenza laboratory tests that are positive;\\\\nThe proportion of visits to physicians for influenza-like illness;\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of influenza-associated deaths among children; and\\\\nThe influenza-associated hospitalization rate among children.\\\\nA flu season�s severity is determined by comparing these measures with previous seasons.']\n",
      "['From October 1, 2006 to May 19, 2007, widespread** flu activity was reported in a total of 41 states across all regions of the country.']\n",
      "['During the past 31 years, flu activity in the United States has peaked in February 45 percent of the time.']\n",
      "['Estimates of flu-associated deaths are made by modeling death certificate data from the National Center for Health Statistics and from CDC influenza virus surveillance data.']\n",
      "['Influenza B viruses accounted for 21 percent.']\n",
      "['Fifty percent of the influenza B viruses characterized as belonging to the B/Victoria lineage were well matched to the influenza B component of the 2006-07 flu vaccine.']\n",
      "['The number of flu-associated deaths among children reported during the 2006-07 flu season can be found in the']\n",
      "['The flu shot is approved for children 6 months of age and older.']\n",
      "['In January 2007, the Council of State and Territorial Epidemiologists voted to add human infections with novel influenza A viruses to the list of nationally notifiable diseases and conditions reportable to the National Notifiable Disease Surveillance System.']\n",
      "['Early detection and timely reporting of human infections with novel influenza A viruses will allow for rapid assessment of the situation and early implementation of the appropriate public health responses.']\n",
      "['When compared with the previous three seasons, the 2007-2008 season was similar in severity to the 2004-2005 flu season in terms of the percentage of deaths due to pneumonia and flu, pediatric hospitalization rates, and the percentage of visits to outpatient clinics for flu-like illness.']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe level of reported activity within each state;\\\\nThe proportion of influenza laboratory tests that are positive;\\\\nThe proportion of visits to physicians for influenza-like illness;\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of influenza-associated deaths among children; and\\\\nThe influenza-associated hospitalization rate among children']\n",
      "['In 16 of the past 26 years, the U.S. flu season has peaked in February or later, making this year pretty typical in terms of the timing of the peak.']\n",
      "['In February, when the flu season peaked, widespread* flu activity was reported in all 50 states across all regions of the country.\\\\n*Widespread flu activity is defined as increased flu-like activity or flu outbreaks in at least half of the regions in a state with recent laboratory evidence of flu in the state.']\n",
      "['Influenza A viruses accounted for 71% of the specimens testing positive for flu by public health laboratories while influenza B viruses accounted for 29%.\\\\nEarly in the season, influenza A (H1N1) viruses predominated, however, as the season progressed, an increasing proportion of sub-typed* influenza A viruses were influenza A (H3N2) viruses.']\n",
      "['For this reason, the World Health Organization and the Vaccines and Related Biologicals Advisory Committee in the U.S. Food and Drug Administration recommended that the influenza A (H3N2) component of the 2007-2008 influenza vaccine would remain the same as the previous season because influenza A (H3N2) viruses similar to the vaccine strain were still circulating and no other candidate reference strains were available.']\n",
      "['In addition, it�s important to remember that the influenza vaccine contains three virus strains so that even when there is a less than ideal match or lower effectiveness against one strain, the vaccine may protect against the other two viruses.']\n",
      "['There were more uncertainties than usual going into the 2009-2010 flu season because of the emergence of the 2009 H1N1 influenza virus (previously called �novel H1N1� or �swine flu�) in the spring of 2009.']\n",
      "['The number of states reporting widespread influenza activity peaked at 49 at the end of October, and decreased to zero by the beginning of January.']\n",
      "['The 2009-10 influenza season was relatively less severe among people 65 years and older than compared with usual flu seasons.']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe number and proportion of flu laboratory tests that are positive;\\\\nThe proportion of visits to physicians for influenza-like illness (ILI);\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of flu-associated deaths among children; and\\\\nThe flu-associated hospitalization rate among children and adults.\\\\nA season�s severity is determined by assessing several of these measures and by comparing them with previous seasons.']\n",
      "['If the viruses in the vaccine and the influenza viruses circulating in the community are closely matched, vaccine effectiveness is higher.']\n",
      "['Every year CDC carries out evaluations and collaborates with outside partners to assess the effectiveness of seasonal flu vaccines.']\n",
      "['(For more information about the seasonal flu vaccine virus selection process, visit�Selecting the Viruses in the Influenza (Flu) Vaccine.)']\n",
      "['2009 H1N1 was by far the dominant virus in circulation last season, and the 2009 H1N1 vaccine was a very good match; 99.5% of the 2009 H1N1 virus specimens tested during the season were related to the virus used to develop the 2009 H1N1 vaccine.\\\\nThe 2010-2011 seasonal flu vaccine will protect against the 2009 H1N1 virus and 2 other flu viruses.']\n",
      "['Samples of viruses collected from around the United States and the world are studied to determine if they are resistant to any of the four FDA-approved influenza antiviral drugs.\\\\nCDC routinely collects viruses through a domestic and global surveillance system to monitor for changes in influenza viruses.']\n",
      "['Because a certain age group may be hit harder by one type of influenza virus than another (for example, the 2009 H1N1 virus has disproportionately affected people younger than 65 years of age than those older than 65 whereas H3N2 virus often affects those older than 65 years), the 2010-2011 influenza season had a substantial health effect on every age group.\\\\nFlu seasons are unpredictable in a number of ways, including when they begin, how severe they are, how long they last, which viruses will spread, and whether the viruses in the vaccine match flu viruses that are circulating.\\\\nAdditional information about flu activity during the 2010-2011 season can be found in the MMWR article']\n",
      "['The peak number of states reporting widespread or regional activity during the previous three seasons has ranged from 49 to 50 states.\\\\n*Regional activity is defined as increased ILI or flu outbreaks and recent laboratory-confirmed flu in at least two but less than half of the regions in a state with recent laboratory evidence of flu in those regions.']\n",
      "['Additional information about severity of the 2010-2011 season can be found in the MMWR article']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe number and proportion of flu laboratory tests that are positive;\\\\nThe proportion of visits to physicians for influenza-like illness (ILI);\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of flu-associated deaths among children; and\\\\nThe flu-associated hospitalization rate among children and adults.\\\\nA season�s severity is determined by assessing several of these measures and by comparing them with previous seasons.']\n",
      "['Although influenza A (H3N2) viruses predominated in the United States during the 2010-2011 season, high levels of 2009 influenza A (H1N1) and influenza B viruses circulated as well.']\n",
      "['In general, the highest vaccine effectiveness is seen among young healthy adults and older children.']\n",
      "['CDC is currently conducting annual vaccine effectiveness studies among persons of all age groups recommended for annual vaccination (i.e., all aged 6 months and older).']\n",
      "['Of the viruses tested, 99.8% of the influenza A (H1N1) viruses, 96.8% of the influenza A (H3N2) viruses, and 94% of the influenza B viruses were similar to the components of the 2010-2011 season�s vaccine.\\\\nFlu viruses are constantly changing (called antigenic drift) � they often change from one season to the next or they can even change within the course of one flu season.']\n",
      "['CDC also worked with the state public health departments and the World Health Organization to collect additional information on antiviral resistance in the United States and worldwide.']\n",
      "['Novel influenza A virus infections include all human infections with influenza A viruses that are different from currently circulating human influenza H1 and H3 viruses.']\n",
      "['The season began late and was mild compared to most previous seasons for which surveillance data is available.\\\\nFlu seasons are unpredictable in a number of ways, including when they begin, how severe they are, how long they last, which viruses will spread, and whether the viruses in the vaccine match flu viruses that are circulating.']\n",
      "['In terms of ILI, this not only the shortest time at or above baseline, but it�s also the lowest �peak� ever recorded.']\n",
      "['Since 2004 the number of pediatric deaths has ranged from a low of 37 deaths during the 2011-2012 season, to a high of 288 deaths reported during the 2009-2010 season, which included pediatric deaths occurring during the 2009 H1N1 pandemic.\\\\nRates of influenza-associated hospitalizations\\\\nDuring the 2011-2012 season, the highest rates of hospitalizations were in people 65 years and older (30 per 100,000) and in children 0-4 years old (14 per 100,000).']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of flu-associated deaths among children;\\\\nThe proportion of visits to physicians for ILI;\\\\nThe flu-associated hospitalization rate among children and adults; and\\\\nThe number and proportion of flu laboratory tests that are positive.\\\\nA season�s severity is determined by assessing several of these measures and by comparing them with previous seasons.']\n",
      "['Over the course of the season, predominant viruses varied from region to region and between states, but nationally, influenza A (H3N2) influenza viruses predominated.']\n",
      "['Final vaccine effectiveness (VE) estimates for the 2011-2012 influenza season found that influenza vaccine was 47% (95% CI, 36% to 56%) effective at preventing medically-attended acute respiratory illnesses caused by circulating influenza A and B viruses in people of all ages.']\n",
      "['The current influenza vaccine is recommended because it is the best way to prevent influenza infections.']\n",
      "['During years when the viruses in the vaccine and circulating viruses are very well matched, it�s possible to measure substantial benefits from vaccination in terms of preventing influenza illness.']\n",
      "['CDC has been working with researchers at universities and hospitals since the 2003-2004 influenza season to estimate how well influenza vaccine works through observational studies using laboratory-confirmed influenza as the outcome.']\n",
      "['The information collected assisted in making informed public health policy recommendations.\\\\nBy the end of the 2011-2012 season, almost all (98.6%) of the 2009 H1N1 influenza viruses tested for antiviral resistance at CDC were susceptible to oseltamivir (Tamiflu�), and all 2009 H1N1 influenza viruses tested were susceptible to zanamivir (Relenza �).']\n",
      "['One case was in a person who reported close contact with swine preceding symptom onset; both patients are fully recovered.\\\\nSince July 2012, there have been outbreaks of H3N2 variant viruses with the matrix (M) gene from the 2009 H1N1 pandemic virus in multiple U.S. states.']\n",
      "['Influenza-like-illness rose quickly to well above the baseline of expected activity and remained elevated for 15 consecutive weeks, making this season slightly longer than average.\\\\nAdditional information about flu activity during the 2012-2013 season can be found in 2012-2013 Flu Season Draws to a Close and in the MMWR article Influenza Activity � United States, 2012-13 Season, and Composition of the 2013-14 Influenza Vaccine.']\n",
      "['While flu activity can vary across the country, influenza activity peaked nationally in late December, when 38.2% of respiratory specimens were influenza-positive and the peak percentage of outpatient visits for ILI was 6.1%.']\n",
      "['Overall, the 2012-2013 season was moderately severe, with a high percentage of outpatient visits for ILI, high rates of hospitalization (particularly among people 65 years and older), and more reported deaths attributed to pneumonia and influenza compared with recent years.\\\\nPneumonia and influenza related deaths in adults and children were tracked through the 122 Cities Mortality Report System.']\n",
      "['Based on available data from U.S. influenza surveillance systems monitored and reported by CDC, the severity of a flu season can be judged according to a variety of criteria, including:\\\\nThe number and proportion of respiratory specimens that are influenza-positive;\\\\nThe proportion of visits to physicians for ILI;\\\\nThe proportion of all deaths that are caused by pneumonia and flu;\\\\nThe number of flu-associated deaths among children; and\\\\nFlu-associated hospitalization rates.\\\\nA season�s severity is determined by assessing several of these measures and by comparing available data with previous seasons.']\n",
      "['Over the course of the entire 2012�2013 season, influenza A (H3N2) viruses predominated nationally, followed by influenza B viruses; 2009 influenza A (H1N1) viruses were identified less frequently.\\\\nInfluenza A viruses predominated until the end of February 2013, after which influenza B viruses were detected more often.\\\\nThe relative proportion of each type and subtype varied by geographic region and by week.']\n",
      "['While influenza can be serious for everyone, hospitalization data indicate people 65 and older were more severely impacted by the 2012-2013 flu season, relative to other age groups.\\\\nThis is consistent with previous observations of the burden of flu illness in the elderly: data from statistical modeling studies looking at flu seasons from 1979 to 2001 estimate that as many as 60% of flu-related hospitalizations occur among people 65 and older.']\n",
      "['These infections in humans were mostly associated with prolonged exposure to pigs at agricultural fairs.\\\\nDuring the 2012�13 influenza season, two additional H3N2v cases were reported, bringing the total number of H3N2v cases to 309.']\n",
      "['The information assists CDC in making informed recommendations for treatment and prevention of influenza in the United States.']\n",
      "['More information about flu activity during the 2013-14 season can be found in FluView and the MMWR report']\n",
      "['During the 2013-2014 season, influenza A (H3N2), 2009 influenza A (H1N1), and influenza B viruses circulated in the United States.']\n",
      "['Hospitalization rates among those aged 50 to 64 years were higher than those seen during the 2009 pandemic and in any year since.']\n",
      "['(This excludes the 2009 pandemic, when 348 pediatric deaths were reported to CDC during April 15, 2009, through October 2, 2010.)']\n",
      "['This VE estimate means that getting a flu vaccine this season reduced the vaccinated population�s risk of having to go to the doctor because of the flu by 60% for both children and adults.\\\\nEffectiveness against the flu A �2009 H1N1� virus, which was the predominating flu virus during the 2013-14 flu season, was 62% (95% CI: 53% to 69%) for children and adults.']\n",
      "['CDC is currently conducting annual vaccine effectiveness studies among persons of all age groups recommended for annual vaccination (i.e., all aged 6 months and older).']\n",
      "['Vaccine for the 2014-2015 season will be available in late summer and in the fall.']\n",
      "['Information about the number of seasonal flu vaccine doses distributed this season is available at Seasonal Flu Vaccine & Total Doses Distributed.\\\\nIn May 2013, flu vaccine manufacturers projected about 138-145 million doses would be available for the U.S. market during the 2013-214 season.']\n",
      "['However, there is a brand that is approved for children as young as 6 months old and up.\\\\nA standard dose trivalent shot containing virus grown in cell culture, which is approved for people 18 years and older.\\\\nA standard dose trivalent shot that is egg-free, which is approved for people 18 through 49 years of age.\\\\nA high-dose trivalent shot, which is approved for people 65 and older.\\\\nA standard dose intradermal trivalent shot, which is injected into the skin instead of the muscle and uses a much smaller needle than the regular flu shot, approved for people 18 through 64 years of age.\\\\nThe quadrivalent flu vaccine protects against two influenza A viruses and two influenza B viruses.']\n",
      "['Each year, these viruses are used to produce seasonal influenza vaccine.\\\\nThe 2013-2014 trivalent influenza vaccine was made from the following three viruses:\\\\nan A/California/7/2009 (H1N1)pdm09-like virus;\\\\nan A(H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011;\\\\na B/Massachusetts/2/2012-like virus.\\\\nIt is recommended that the quadrivalent vaccine containing two influenza B viruses include the above three viruses and a B/Brisbane/60/2008-like virus.\\\\nCDC did not recommend any one flu vaccine over another.']\n",
      "['This occurs every season.']\n",
      "['This is the influenza A (H3N2) component of the Northern Hemisphere quadrivalent and trivalent vaccines for the 2013-2014 season.\\\\n269 (70.6%) of the 381 influenza B viruses tested belonged to the B/Yamagata lineage of viruses.']\n",
      "['Additionally, CDC is working with the state public health departments and the World Health Organization to collect additional information on antiviral resistance in the United States and worldwide.']\n",
      "['CDC and its partner laboratories detected a small number (1.2%) of 2009 H1N1 influenza viruses in the United States during the 2013-14 season that are resistant to the antiviral drug oseltamivir (trade name Tamiflu).']\n",
      "['CDC continues to work closely with its partners at the state level to monitor for antiviral resistant flu viruses this season.']\n",
      "['The season was a relatively early in terms of timing, with influenza activity increasing through November and December, and peaking in late December.\\\\nThe frequency of outpatient visits to doctors for influenza like illness (ILI) went above the national baseline the week ending November 22, 2014 and remained elevated for 20 consecutive weeks, making the season longer than average and the longest in more than a decade.']\n",
      "['The timing of flu is unpredictable and can vary in different parts of the country and from season to season.']\n",
      "['Based on available data from U.S. influenza surveillance systems that are monitored and reported on by CDC, the severity of a flu season is judged according to a variety of criteria, including:\\\\nThe number and proportion of respiratory specimens that are influenza-positive;\\\\nThe proportion of visits to healthcare providers that are due for ILI;\\\\nThe proportion of all deaths that are caused by pneumonia and influenza ;\\\\nThe number of flu-associated deaths among children; and\\\\nFlu-associated hospitalization rates.\\\\nCDC assesses the severity of a season by comparing the data from these measures with data from previous seasons.']\n",
      "['For more information, see Overview of Influenza Surveillance in the United States.\\\\nCDC also uses modeling studies to estimate numbers of flu-related deaths, but these studies apply only to past seasons and are not done each year.']\n",
      "['Some of the challenges in counting influenza-associated deaths include the following: the sheer volume of deaths to be counted; the fact that not everyone that dies with an influenza-like illness is tested for influenza; and the fact that influenza-associated deaths are often a result of complications secondary to influenza and underlying medical problems, and this may be difficult to sort out.']\n",
      "['Influenza B viruses predominated from the week ending February 28, 2015 (week 8) through the week ending May 23, 2015 (week 20).\\\\nThe relative proportion of each type and subtype varied by geographic region and by week.']\n",
      "['While influenza virus infection can be serious for anyone, hospitalization data indicate people 65 years and older were more severely impacted by the 2014-2015 flu season, relative to other age groups and relative to previous seasons.\\\\nAmong people 65 years and older, there were an estimated 8.3 million illnesses, 4.7 million medical visits and 758,000 flu hospitalizations during the 2014-2015 season.']\n",
      "['As of February 1, 2016, a total of 148 laboratory-confirmed, influenza-associated pediatric deaths occurring during the 2014-2015 flu season were reported to CDC from 41 states and New York City.\\\\nSince influenza-associated pediatric mortality became a nationally-notifiable condition during the 2004-2005 season, the total number of influenza-associated pediatric deaths has ranged from 34 to 171.']\n",
      "['One infection with an influenza A (H3N2) variant virus (H3N2v) occurred during the week ending October 18, 2014 (week 42) in Wisconsin, and one infection with an influenza A (H1N1) variant (H1N1v) virus was reported to CDC during the week ending January 24, 2015 (week 3), from Minnesota.']\n",
      "['Some seasonal flu vaccines were formulated to protect against four flu viruses (quadrivalent flu vaccines).']\n",
      "['Recommendations for the 2014-2015 season are available in the Morbidity and Mortality Weekly Report (MMWR) Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) � United States, 2014-15 Influenza Season.']\n",
      "['Of those projected doses, manufacturers estimated that 76 million doses would be quadrivalent flu vaccine.']\n",
      "['In addition to the above three, quadrivalent vaccines were made to protect against an B/Brisbane/60/2008-like virus.\\\\nVaccines that give protection against three viruses are called trivalent vaccines.']\n",
      "['The adjusted VE estimate against influenza A (H3N2) viruses for all ages was 13%.\\\\nReduced protection against influenza A (H3N2) viruses for the 2014-2015 season was attributed to the fact that more than 80% of circulating influenza A (H3N2) viruses analyzed at CDC were different or �drifted� from the recommended influenza A (H3N2) vaccine virus.\\\\nThese vaccine effectiveness estimates were derived from data collected']\n",
      "['However, the vaccine worked well against about one-third of circulating influenza A (H3N2) viruses that were similar to the recommended vaccine virus and against influenza A (H1N1) and influenza B viruses.']\n",
      "['Because of these factors, there is always the possibility of a less than optimal match between circulating viruses and the viruses in the vaccine.\\\\nWhen the vaccine viruses for 2014-2015 were selected, A/Texas/50/2012 was the most common circulating influenza A (H3N2) virus, so it was chosen to be included in the vaccine.']\n",
      "['One of the things that CDC looks for are changes in viruses that would make antiviral drugs less effective in treating or preventing infection.']\n",
      "['During the 2014-2015 season, CDC completed multiple studies on the effectiveness of both the flu shot and the nasal-spray flu vaccine.']\n",
      "['While H3N2 viruses predominated early in the season, H1N1 viruses were the most common later in the season and were the predominant virus for the entire season.']\n",
      "['The timing of flu is unpredictable and can vary in different parts of the country and from season to season.']\n",
      "['The percentage of deaths attributed to P&I peaked at 7.9% during the week ending March 19, 2016 (week 11).']\n",
      "['Since influenza-associated pediatric mortality became a nationally-notifiable condition during the 2004-2005 season, the total number of influenza-associated pediatric deaths has ranged from 37 to 171.']\n",
      "['However, influenza A (H3N2), A(H1N1)pdm09 and influenza B viruses from both lineages were detected last season.']\n",
      "['There was no evidence of human-to-human transmission associated with any of these reports.']\n",
      "['As of February 26, 2016, manufacturers reported having shipped approximately 146.4 million doses of flu vaccine.']\n",
      "['The overall VE against A(H1N1)pdm09 was 41% and the overall VE against influenza B was 55%.']\n",
      "['Laboratory data show that most of the circulating flu viruses were like the viruses recommended for the 2015-2016 influenza vaccines.']\n",
      "['High levels of resistance to the adamantanes (amantadine and rimantadine) persisted among influenza A viruses.']\n",
      "['The revisions were implemented with the goal of yielding a more balanced and comprehensive picture of antigenic, genetic, and antiviral properties of the main groups of flu viruses circulating in the United States.']\n",
      "['Morbidity and Mortality Weekly Reports (MMWR) CDC Flu Reports & Spotlights']\n",
      "['Getting an annual flu vaccine is the first and best way to protect yourself and your family from the flu.']\n",
      "['This time of year is called “flu season.” In the United States, flu viruses are most common during the fall and winter months.']\n",
      "['Also, if you have a loved one who is at high risk of flu complications and they develop flu symptoms, encourage them to get a medical evaluation for possible treatment with flu antiviral drugs.']\n",
      "['Flu vaccine is produced by private manufacturers, so the timing of vaccine availability depends on when production is completed.']\n",
      "['Antiviral drugs are prescription drugs that can be used to treat flu illness.']\n",
      "['The Epidemiology and Prevention Branch in the Influenza Division at CDC collects, compiles and analyzes information on flu activity year round in the United States and produces FluView, a weekly influenza surveillance report, and FluView Interactive, which allows for more in-depth exploration of flu surveillance data.']\n",
      "['However, during the 2014–2015 flu season in the United States, several hundred cases were reported to CDC, representing the largest number of reported cases ever.']\n",
      "['The 2017-18 season was the first season to be classified as a high severity across all age groups.']\n",
      "['Influenza-like illness (ILI) was at or above the national baseline for 19 weeks, making the 2017-2018 season one of the longest in recent years.']\n",
      "['During the 2017-2018 season, the percentage of deaths attributed to pneumonia and influenza (P&I) was at or above the epidemic threshold for 16 consecutive weeks.']\n",
      "['Since flu-associated deaths in children became a nationally notifiable condition in 2004, the total number of flu-associated deaths among children during one season has ranged from 37 (during the 2011-2012 season) to 186 (during the 2017-18 season, as of April 19, 2019); this excludes the 2009 pandemic, when 358 pediatric deaths from April 15, 2009 through October 2, 2010 were reported to CDC.']\n",
      "['Estimates on the total number of flu-related hospitalizations during 2017-2018 will be available in fall 2018.']\n",
      "['However, influenza B viruses became more commonly reported than influenza A viruses in early March 2018 through May 2018.']\n",
      "['As of February 23, 2018, manufacturers reported having shipped approximately 155.3 million doses of flu vaccine; a record number of flu vaccine doses distributed.']\n",
      "['The overall vaccine effectiveness (VE) of the 2017-2018 flu vaccine against both influenza A and B viruses is estimated to be 40%.']\n",
      "['The majority of the influenza viruses collected from the United States during the 2017-2018 flu season were characterized antigenically and genetically as being similar to the cell-grown reference viruses representing the 2017–18 Northern Hemisphere influenza vaccine viruses.']\n",
      "['Since October 1, 2017, CDC tested 1,147 influenza A(H1N1)pdm09, 2,354 influenza A(H3N2), and 1,118 influenza B viruses for resistance to antiviral medications (i.e., oseltamivir, zanamivir, or peramivir).']\n",
      "['Over the course of flu season, CDC studies samples of circulating flu viruses to evaluate how close a match there is between viruses used to make the flu vaccine and circulating flu viruses.']\n",
      "['The\\xa0burden of influenza on the United States can vary widely from season to season and is determined by a number of factors including the characteristics of circulating viruses, the timing of the season, population immunity to circulating viruses, how well flu vaccines are working, and how many people have gotten vaccinated.']\n",
      "['Limited antigenic data on recently circulating viruses are available at this point in the season, and the data suggest similarity of the circulating influenza A(H1N1)pdm09 and B/Yamagata viruses tested so far to the vaccine viruses.']\n",
      "['In trying to balance the need to get many people vaccinated before flu activity begins with concerns about potential waning of vaccine-induced immunity during the flu season, CDC and ACIP recommend that vaccination be offered by the end of October.']\n",
      "['While the use of cell-grown vaccine viruses and cell-based technology may offer the potential for better protection over traditional, egg-based flu vaccines because they result in vaccine viruses that are more similar to flu viruses in circulation, there are no vaccine effectiveness data to support this.']\n",
      "['This time of year is called “flu season.” In the United States, flu viruses are most common during the fall and winter months.']\n",
      "['There is no expressed preference for any flu shot or the nasal spray vaccine.']\n",
      "['During years when the viruses in the flu vaccine and circulating flu viruses are well matched, it’s possible to measure substantial benefits from flu vaccination in terms of preventing flu illness.']\n",
      "['Baloxavir is approved for the treatment of acute uncomplicated flu in people 12 years and older who have had flu symptoms for less than 48 hours.']\n",
      "['The Epidemiology and Prevention Branch in the Influenza Division at CDC collects, compiles and analyzes information on flu activity year round in the United States and produces FluView, a weekly flu surveillance report, and FluView Interactive, which allows for more in-depth exploration of flu surveillance data.']\n",
      "['For the 2020-21 flu season, CDC provided weekly updates on the number of flu vaccine doses distributed, vaccination coverage estimates for children, and the number of doses administered in pharmacies and doctor’s offices.']\n",
      "['Nationally, flu activity during the 2021-2022 season began to increase in November and remained elevated until mid-June with two different waves of influenza A(H3N2) virus activity occurring; the first peaked in late December 2021, and the second in April 2022.']\n",
      "['While the number of B/Victoria viruses that circulated during the 2021-22 season was small, the majority of the B/Victoria viruses characterized were antigenically similar to the vaccine reference virus.']\n",
      "['For more information, visit\\xa0Influenza Vaccine for the 2021-2022 Season | FDAexternal icon For the 2021-2022 flu season, there was no recommended preference for any one vaccine over another, and providers could administer any licensed, age-appropriate flu vaccine (IIV, RIV4, or LAIV4).']\n",
      "['The use of adamantanes (amantadine and rimantadine) is not recommended for treatment and prevention of influenza A virus infection because of persistently high prevalence of resistance among circulating influenza A(H1N1)pdm09 and influenza A(H3N2) viruses (the adamantanes are not effective against influenza B viruses).\\\\nDuring the 2021-2022, 0.2% of the viruses tested had markers associated with reduced susceptibility to the antiviral drugs recommended for treatment of influenza by CDC.']\n",
      "['For the 2021-22 flu season, CDC provided weekly updates on the number of flu vaccine doses distributed, vaccination coverage estimates for children, and the number of doses administered in pharmacies and doctor’s offices.']\n",
      "['After discussions with public health partners during the summer of 2021, the decision was made to permanently retire this surveillance component due in part to the fact that the systems used to determine the level of spread remain significantly altered by changes in healthcare seeking behavior and testing changes brought on by the COVID-19 pandemic, and a measure of geographic spread was not necessary anymore given improvements in national influenza surveillance systems in recent years.']\n",
      "['A couple of things are different for the 2023-2024 influenza (flu) season:']\n",
      "['P&I (pneumonia and/or influenza) no longer measures the impact of influenza in the same way it had prior to the COVID-19 pandemic, and the PIC (pneumonia, influenza and/or COVID) measure is largely being driven COVID-19 activity making it difficult to monitor the impact of influenza using that measure.']\n",
      "['B/Yamagata flu viruses have not circulated in the population since March 2020, so protection from trivalent and quadrivalent flu vaccines is expected to be similar.']\n",
      "['It is also possible to be sick with multiple flu viruses, like influenza A and B, at the same time.']\n",
      "['The table provides the total number of COVID-19 and flu coinfections as well as the total number of flu and RSV coinfections reported during this time frame among patients hospitalized with laboratory-confirmed influenza virus infection.']\n"
     ]
    }
   ],
   "source": [
    "for sentences in all_tokenized_sentences:\n",
    "\n",
    "    lxr = LexRank(sentences)\n",
    "\n",
    "    summary_cont = lxr.get_summary(sentences, threshold=None)\n",
    "    \n",
    "    print(summary_cont)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Text Rank"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting summa\n",
      "  Downloading summa-1.2.0.tar.gz (54 kB)\n",
      "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m54.9/54.9 kB\u001b[0m \u001b[31m1.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0ma \u001b[36m0:00:01\u001b[0m\n",
      "\u001b[?25h  Preparing metadata (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25hRequirement already satisfied: scipy>=0.19 in /Users/tongfah/anaconda3/envs/nlp/lib/python3.11/site-packages (from summa) (1.11.4)\n",
      "Requirement already satisfied: numpy<1.28.0,>=1.21.6 in /Users/tongfah/anaconda3/envs/nlp/lib/python3.11/site-packages (from scipy>=0.19->summa) (1.26.3)\n",
      "Building wheels for collected packages: summa\n",
      "  Building wheel for summa (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25h  Created wheel for summa: filename=summa-1.2.0-py3-none-any.whl size=54389 sha256=ac8efb6a486344a20db1e23703a954d32a9e8ef5d17ff8e53cdab3a1d1ad341f\n",
      "  Stored in directory: /Users/tongfah/Library/Caches/pip/wheels/10/2d/7a/abce87c4ea233f8dcca0d99b740ac0257eced1f99a124a0e1f\n",
      "Successfully built summa\n",
      "Installing collected packages: summa\n",
      "Successfully installed summa-1.2.0\n"
     ]
    }
   ],
   "source": [
    "!pip install summa"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "text = content['Content'].values[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "from summa.summarizer import summarize\n",
    "summarizer = summarize(text, ratio=0.05)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The first report of regional flu activity came from the southeastern United States during the first week of November. Regional flu activity is defined as increased flu-like activity or flu outbreaks in at least two (but fewer than half) of the regions in a state with recent laboratory evidence of flu in those regions.\n"
     ]
    }
   ],
   "source": [
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "print(summarizer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "nlp",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
